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Abstract 
Jimmy Phuong 
Structured Application of Biological Ontologies to Annotate  
High-Throughput Screening Assays and their Targets of Activity 
(Under the direction of Matthew Martin) 
 
High-throughput screening (HTS) assays have changed the pace of chemical data collection, 
enabling assessments at various levels of biological relevance. EPA’s ToxCast Program has 328 
assays (experiments) generating 541 assay components (readouts), which produces 795 assay 
component endpoints (analyses), with intentions to increase the number of assays and the 
number of substances tested. As new assays are developed, it becomes a challenge to 
communicate what kind of data and features are associated with each assay. This report uses the 
BioAssay Ontology and other publicly available ontologies to produce the ToxCast Assay 
Annotation, a structured resource for descriptive information that uses controlled vocabulary to 
aid in the communication and use of ToxCast HTS assay data. Organized by 34 annotations 
including ‘assay design type’ and ‘detection technology type’, this structure allows for a concise 
reference to the pertinent attributes of an assay. Additionally, the perspective differences 
between the technological and intended target are separately captured. This structured annotation 
also allows for the identification of comparable ToxCast assay endpoints, and offers the potential 
to link with other HTS data repositories. 
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Chapter 1 
Literature Review 
Chemical Testing Demand and High-Throughput Screening Assays 
The foremost concern about the chemicals in the environment is that most are 
insufficiently evaluated for their bioactivity and potential hazards. Since 1976, the Toxic 
Substances Control Act (TSCA) inventory has registered over 66,000 chemicals manufactured in 
or imported into the United States (Congress 1976). TSCA mandates the United States 
Environmental Protection Agency (EPA) to protect the public from adverse human health or 
environmental outcomes downstream of these chemicals. For the past 40 years, these risk 
assessments used any bioactivity and adverse effect information available, which largely relied 
on expensive, time-consuming animal model experiments. Due to this slow pace and unevenness 
of chemical testing, a small fraction of chemicals becomes data-rich while the vast majority 
remains with little or no available data. 
The National Academy of Sciences’ (NAS) National Research Council (NRC) has 
addressed the current chemical testing paradigm with the desire to move in a direction that 
reduces the number of animals used, reduces the cost and testing time, and increases the 
mechanistic understanding of the chemical effects (NRC 2007). While encouraging the recycled 
use of existing in vivo data, these desires have turned the scientific and regulatory communities 
towards in vitro assays, particularly high-throughput screening (HTS) and high content screening 
(HCS) assays. Compared with in vivo studies, HTS and HCS assays require smaller amounts of 
testing space and volumes of testing material. Integrated with new methodologies such as 
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toxicogenomics, bioinformatics and computational toxicology, the data collected through HTS 
and HCS assays can more easily enable mechanistic assessments. The assays may probe human 
genes, cells, or tissues to reflect on how chemicals may elicit perturbations at the molecular level 
or cumulatively as pathway responses (Dix et al. 2007; Morisseau et al. 2009; Judson et al. 2010; 
Kavlock et al. 2012). 
At its foundation, an assay is a manufactured test to detect perturbations away from the 
normal biological activity. The activity tested will be dependent on how the assay is conducted 
and what it measures. HTS assays are assays that have been optimized to allow simultaneous 
testing while reducing the cost and time expenditures. Consider a HTS assay conducted in a 384 
well-plate as the optimized form of the same assay that was previously conducted in single test 
tubes—the data yield is in orders of magnitude faster. HTS methodologies are predominantly 
drug discovery approaches; however, reapplying these same approaches towards environmental 
chemicals can help address the number of data gaps existing for the large portion of 
environmental chemicals (Dix et al. 2007; Judson et al. 2009). 
In response to the NRC report (2007), EPA has chosen approximately 10,000 chemicals 
to be considered for the ToxCast screening and prioritization program (Dix et al. 2007; Judson et 
al. 2009). Out of the TSCA inventory, these chemicals were selected due to medium- and high-
production volumes (exceeding 10,000 lb/year), known industrial functions as pesticides actives, 
presence in the environment as drinking-water contaminants, or known inert chemicals (Judson 
et al. 2009). Some of these chemicals are data-rich, enabling a way to compare the assay results 
with precedent knowledge of the chemicals’ activities (Martin et al. 2011). In ToxCast, testing 
would occur in phases; each ToxCast phase is a separate group of nominated chemical that will 
3 
 
be tested through a large, diverse number of HTS and HCS assays. In addition to ToxCast, EPA 
is an active participant in Toxicity Testing in the 21
st
 Century consortium (Tox21), an Inter-
Agency collaboration that takes a different strategy towards executing chemical tests. Using the 
latest in automated HTS technologies, Tox21 tests all 10,000 chemicals through small groups of 
assays; each Tox21 phase is a different set of assays (Huang et al. 2011). From these two 
programs, at each phase, ToxCast would provide a broad view of chemical activity across 
diverse biological endpoints while Tox21 would provide a means to rank the 10,000 chemicals 
using assays that target endpoints of high concern. 
Data Storage 
With the large number of chemicals to be tested and even larger nest of HTS data 
expected, data storage becomes a big factor. To list them explicitly, there would be the chemical 
or substance identifiers, the structural features for each chemical or substance, the plate maps for 
each tested chemical plate, the assay identifiers, the readout data and the analyzed data. To cover 
these different needs, separate databases were devoted to capture the information. Judson et al. 
(2012) mentions that ToxCast plans to disseminate the data storage to a number of different 
databases of specific function. The EPA Distributed Structure-Searchable Toxicity (DSSTox) 
program is dedicated to the chemical structure and linkage between chemical structures to 
external data sources (Williams-DeVane et al. 2009; Judson et al. 2012). The EPA ToxCast 
Database (ToxCastDB) would serve as the data repository for both the ToxCast assay data as 
well as descriptive information about each assay. As a key component for biological modeling, 
the EPA ToxRef Database (ToxRefDB), a database devoted to systematic curation of in vivo 
experimental outcomes, would be the anchorage point between the ToxCast chemicals and the 
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historic toxicity endpoint information that may be available for them (Martin et al. 2009). 
Similarly, the EPA ExpoCast Database (ExpoCastDB) stores data pertinent for exposure and 
environmental presence modeling. Separately, the EPA Aggregate Computational Toxicology 
Resource (ACToR) database combines the information from each of these EPA databases and to 
other publicly available data sources. In general, these databases can communicate or be queried 
via chemical structure and identity. This is a chemical-centric, test substance oriented point of 
view, which is not developed for assay-centric or target-centric options. 
Assay Terminology 
With the push for advancing chemical testing, more questions and challenges about HTS 
and HCS assays arise. The language for different aspects of in vitro assays was not formally 
established to enable assay-centric search options. Perhaps more pertinent to ACToR and 
ToxCastDB, this area of assay terminologies gets revisited when trying to communicate 
similarities and differences between assays. For instance, protein assays were previously 
synonymous with binding assays. Now, with new assay technologies developed to probe 
different facets of protein function, a protein assay seems vague. Within ToxCast, a protein assay 
could now mean enzyme-substrate reactions, receptor-ligand binding, protein expressions by 
enzyme-linked immunosorbent assays (ELISA), changes in protein-protein interaction, or even a 
marker protein for cytotoxicity or a pathway response (Kavlock et al. 2012). This area could 
continue to propagate as new, abstract ways to consider a protein’s biological processes and 
systems biological impact are developed. 
Beyond the assay technology, the content readout has shifted towards more multiplexed 
and multiparametric approaches. A single assay could now be equipped to interrogate a battery 
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of targets (Romanov et al. 2008; Houck et al. 2009; Giuliano et al. 2010; Martin et al. 2010; 
Rotroff et al. 2010). This is the real challenge: communicating to the general public what the 
readouts of increasingly complex assays are with respect to the data already available from the 
previous generation of single readout assays. This inherently demands a definition for the 
minimum amount of information for an assay, for which there currently is not an agreed upon 
standard across different technologies (Visser et al. 2011). 
Moreover, different HTS campaigns have their own approaches towards describing and 
categorizing their in vitro assay libraries. The ToxCast program purchases testing data for the 
ToxCast chemical sets from various contract vendors, who have the technology and expertise to 
perform patented assay protocols. Some of the past ToxCast publications emphasized the 
biomedical innovation from assays purchased from different contract vendors while focusing on 
utility of the data for modeling chemical and biological endpoints (Judson et al. 2010; Martin et 
al. 2011; Sipes et al. 2011; Kleinstreuer et al. 2013). Hence, the mechanics, biological 
innovations, and utility behind each HTS assay were separately explained with variations in the 
terminology. A similar scenario can be seen of the Molecular Libraries Program (MLP), an NIH 
funded HTS campaign that began in 2003. MLP uses different testing centers within the 
Molecular Libraries Screening Center Network (MLSCN) to focus on different assay protocols 
then deposits the chemical testing data into PubChem repositories (Wang et al. 2009; Chen and 
Wild 2010). As such, the use of varying vocabulary has preset difficulties in understanding the 
assays and in applying cross-analysis methods (Schürer et al. 2011). 
The ToxCast HTS assays were previously annotated in a number of ways using 
unstructured text. Containing a breadth of initial annotations, these have served as the foundation 
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for chemical-to-pathway modeling and for anchoring in vitro to in vivo outcomes for predictive 
models (Judson et al. 2010; Knudsen and Kleinstreuer 2011; Kleinstreuer et al. 2013). However, 
with exception to the gene target annotations, the use of unstructured text without quality 
controls gave way to mistakes in representation that were later remedied. Visser et al. (2011) has 
described the utility of maintaining quality control checkpoints, a workflow step to inspect for 
annotation mistakes in previous annotations and for annotating new assays moving forward. 
Visser et al. also promotes the use of controlled, ontology vocabulary to help unify synonymous 
concepts, where applicable. In doing so, the use of better annotation terms gets highlighted or, in 
the lack thereof, the usage highlights the need for new concepts and terms. 
Aside from publishing the articles with the HTS and HCS assay data, there are 
communication challenges that sit between access to the data and knowledgeable use of the data. 
There is currently no recognized, uniform guidance for the minimum amount of information (e.g. 
metadata) needed to be supplied with the assay data across technologies (Vempati et al. 2012). 
Alternatively, ontologies provide controlled vocabulary that may address relationships between 
different assay concepts. There are a large number of database schemas and biological ontologies 
currently available within BioPortal (bioportal.bioontology.org) that could provide controlled 
vocabulary for annotation purposes. Among them, the BioAssay Ontology (BAO), an ontology 
created from the University of Miami, has proposed a guidance framework that incorporates 
vocabulary from different ontologies for objectively annotating HTS assay. This includes 
provisions for the assay design, assay formats, detection technologies, perturbagen (further 
referred as the tested chemical), and endpoints (Vempati and Schürer 2004; Visser et al. 2011; 
Vempati et al. 2012). Within each of these annotations, subclasses may branch further, where 
each term has descriptive information provided to explain its contextual usage.  
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While ontologies may change, the ontology’s framework can be reused to guide 
annotations. BAO version 1.6 has been used to annotate the assays deposited into PubChem for 
relevant assay descriptive data (Schürer et al. 2011; Vempati et al. 2012). Schürer et al. (2011) 
has applied these PubChem annotations as the basis for assay promiscuity evaluations, a 
calculation method similar to a principle components analysis (PCA) to determine what 
annotations of the assay are major contributors to the amount of noise and non-specific chemical 
hits.  
Because of this precedence, the use of BAO version 1.6 to annotate assays moving 
forward may enable a uniformed language through which assay comparisons may be made. 
However, several limitations in BAO were noted; the amount of terms incorporated into BAO 
from other ontologies is not representative of each of those full ontologies. This suggests that 
BAO keeps only the fraction of those ontology terms that have been encountered with each 
update; therefore, newer and diverse assays may have concepts and terms outside of BAO’s 
capacities. BAO is currently at version 2.0. Between versions, BAO has incorporated more terms 
from Gene Ontology (GO) biological processes and Cell Line Ontology (CLO) into their 
respective branches. The same creators of BAO have also created the G-Protein Coupled 
Receptor Ontology (BAO-GPCR), enabling BAO annotation terms to link with BAO-GPCR 
terms for concepts relating to G-protein coupled receptors (GPCR).
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Chapter 2 
Introduction 
 
 
Seen as versatile, cost-effective, and a way to gain mechanistic insight, testing chemicals 
in concentration-response using HTS and HCS assays with diverse biological endpoints 
overcomes a number of disadvantages in whole animal toxicity testing (Judson et al. 2009; 
Morisseau et al. 2009). The main advantage in using HTS assays is that novel biological targets 
can be investigate through a wide range of in vitro assay technologies (e.g., receptor binding, 
transcriptional activation, protein fragment complementation). The multiplexed and 
multiparametric approaches make it possible to use a single assay for interrogating a battery of 
targets, allowing for more pathway-based analyses and mechanistic learning all while reducing 
testing cost and time (Romanov et al. 2008; Houck et al. 2009; Giuliano et al. 2010; Martin et al. 
2010; Rotroff et al. 2010). With increased throughput, in vitro assay technologies are key 
strategic tools to generate data on chemical-biological activity and step away from the heavy 
reliance upon preliminary in vivo whole animal testing. 
As HTS technologies continue to improve, questions are raised about how to capture the 
increasing complexity while retaining the ability to relate between assays. Often described non-
uniformly, some HTS assays may have higher minimum information standards than what is 
required for other technologies. Without adopting a consensus structure, the approaches to 
describe assays may vary between different HTS initiatives. These inconsistencies in uses of 
vocabulary can presets communication and cross-analysis difficulties.  
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In the early stages of Tox21, the National Institute for Health (NIH) National Center for 
Advancing Translational Sciences (NCATS) came up with a list of reporting parameters for HTS 
and HCS assays (Inglese et al. 2007). This was a short list meant to minimally capture the 
necessary components for the HTS screening and post-analysis. While the concepts were clear, 
how to address the parameters required more clarity and instruction. Annotations would still 
have used unstructured free-text. 
Since then, BAO has proposed a guidance framework based on the screening information 
produced from MLP. This framework nominates concepts that need to be annotated and 
annotation terms for each annotation to use. What’s more, it captures more than the NCATS 
reporting parameters while clarifying certain parameters that are better separated. Featuring clear 
semantics and hierarchical relationships, BAO makes use of several ontologies of biomedical 
and pharmacological focus and has applied their framework to annotate assays in the public 
domain from PubChem and other data repositories (Vempati and Schürer 2004; Visser et al. 
2011; Vempati et al. 2012). This highlights the BAO framework as a broad and integrative 
foundation for capturing similarities and differences between assays within the realm of toxicity 
testing. 
The ToxCast Assay Annotation was developed to describe features represented in 
ToxCast assay endpoints. Led by the EPA National Center for Computational Toxicology 
(NCCT), ToxCast is tasked to test chemicals in the environment with the purpose of increasing 
the biological-toxicological knowledge and informing chemical-testing decision-making. 
Contracting with various laboratories and platform vendors, the ToxCast Phase I and II chemical 
sets (n=1060) were completely tested through innovative set of assay technologies (Kunkel et al. 
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2004; MacDonald et al. 2006; Hartig et al. 2008; Romanov et al. 2008; Giuliano et al. 2010; 
Huang et al. 2011; Sakamuru et al. 2012; Sipes et al. 2013). Assays vary from simple interactions 
(e.g., biochemical binding or enzyme inhibition/activation) to complex biological reporters (e.g. 
multiple targets, inferred targets, or cellular processes). The discussion on minimum information 
standards has become increasingly technology-oriented (Goetz et al. 2011; Patlewicz et al. 
2013). Adhering to minimum information standards makes a global assay annotation framework 
difficult. Therefore, in annotating the ToxCast assays which have more technological and 
biological diversity than in any screening program before it, it requires a uniform list of 
annotations. Since BAO is the most comprehensive assay-oriented ontology currently available 
among the 370 ontologies in BioPortal (http://bioportal.bioontology.org/), it was applied in a 
structured approach that would allow for expansions to the annotations and annotation terms. 
The primary objective of this study is to demonstrate the role of the ToxCast Assay 
Annotation in understanding and analyzing HTS data. First, we describe the structured approach 
used in the global annotation. Next, we show how these annotations can provide resolution to 
understand the assay identification, design, target, or analysis information. Finally, we report on 
an initial cross-analysis of the chemical-biological activity using the annotation terms. Example 
scenarios are provided to illustrate how design and target annotations can be used to represent 
assay biological and technological space. 
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Chapter 3 
Methods 
Data Sources 
The inventory list of ToxCast assays was obtained from ToxCastDB (Judson et al. 2012). 
The assays used to build the first version of ToxCast Assay Annotation was limited to only those 
that have completed testing and analysis with ToxCast Phase I and II chemical sets. Assays that 
met this criteria were found to belong to the following assay sources: 1) ACEA biosciences 
(ACEA, www.aceabio.com) (Rotroff et al. 2013), 2) Apredica (APR, www.cyprotex.com) (Shah 
et al., in-progress), 3) Attagene (ATG, www.attagene.com) (Romanov et al. 2008; Martin et al. 
2010), 4) Bioseek (BSK, www.bioseekinc.com) (Kunkel et al. 2004; Houck et al. 2009), 5) 
Novascreen (NVS, www.perkinelmer.com) (Knudsen et al. 2011; Sipes et al. 2013), 6) Odyssey 
Thera (OT, www.odysseythera.com) (Yu et al. 2003; MacDonald et al. 2006), and 7) Tox21 
(Huang et al. 2011; Sakamuru et al. 2012). EPA purchases the assay data generated from the 
Assay Sources, while Tox21 provides assay data as part of an interagency collaboration. The 
methodology for each assay was obtained from their respective ToxCast platform manuscripts, 
vendor/program publications, or standard operating procedures (SOPs). For data analysis with 
chemical testing data, the High-Throughput Chemical Screening Data from ToxCast & Tox21 as 
part of the December 2013 ToxCast Phase II Data Release was used (ToxCast 2013). 
Annotation Framework 
The BAO version 1.6 (www.bioassayontology.org) was developed around six concepts of 
biological screening (Schürer et al. 2011; Visser et al. 2011; Vempati et al. 2012). To summarize, 
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(1) perturbagen (perturbing agents that are screened), (2) assay design (the underlying 
methodology and strategy used for detecting a perturbation), (3) assay format (the chemical- and 
biological-features common to the test condition), (4) detection technology (the physical method 
used to detect and record perturbation signals), (5) meta-target (the molecular entity, biological 
process, or event interrogated by the assay), and (6) endpoint (the analyzed measurements, 
parameters and values). For the ease of maintaining the chemical inventory, the ToxCast 
chemical library, representing the perturbagen component, is stored and routinely updated within 
the DSSTox database (Williams-DeVane et al. 2009; Judson et al. 2012); hence, the ToxCast 
Assay Annotation is meant to describe the other five concepts of biological screening. 
The annotations can be separated into four sets of information. These four sets include 
assay identification information (identifiers for each level, the assay source, and peripheral 
catalog information), design information (format, design, and technology aspects that 
decompress the assay’s innovations), target information (various perspectives about the assay’s 
target), and analysis information (how the data were processed and analyzed). Each set of 
information can be further separated into smaller concepts—the individual annotations. Each 
annotation is rationally assigned to one of three levels, which represent the stage of the assay as 
they undergo processing. Each annotation is annotated with an annotation term (the controlled 
vocabulary) with respect to its level. These levels includes: the assay level–the experiment or test 
event, the assay component level—the individual raw readouts within the experiments, and the 
assay component endpoint level—the analyzed readouts which have been data fitted, such as to a 
four-parameter Hill curve. In this way, the assignment puts an annotation as a feature of a certain 
level, a communication option for focusing the amount of information. 
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Figure 1: The annotation workflow 
 
Data Input 
The initial, data entry steps follow the left-and-middle portions of the workflow shown in 
Figure 1. Initially, from the table of ToxCast assay component endpoints, each assay was 
manually annotated to an Excel spreadsheet, following the BAO version 1.6 annotation template 
as a model (Vempati and Schürer 2004). In this format, each column was an assay component 
endpoint obtained from ToxCastDB and each row was an annotation. Thereafter, annotation 
terms were selected in reference to the SOPs or the assay manuscripts. 
After the initial steps the annotations were transitioned to a MySQL relational database 
for better data structure and ease of quality control. The spreadsheet format permitted rigid one-
to-one assignments. This poses problems for the annotations that have one-to-many 
relationships, such as reagents, which were kept semicolon delimited within each cell of the 
spreadsheet format until they could be transitioned. This also allows for the linkages between 
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each annotation to Assay, Assay Component, or assay component endpoints to be defined and 
represented together as a table. 
The ToxCast Assay Annotation MySQL database is mainly comprised of seven tables. 
The Assay Source table provides some description for the contract vendor that performed the 
assays. The Assay, Assay Component, and assay component endpoint tables are analogous to 
their levels, and contain the annotations assigned to the respective level. Reagents, technological 
targets, and intended targets contain one-to-many relationships so they were separated as their 
own tables. Respectively, Assay Reagents, Assay Component Target, and assay component 
endpoint Target were mapped as dependents of the Assay, Assay Component, and assay 
component endpoint tables. 
Quality Control 
Quality control checkpoints to inspect the manual curations occurred at two steps: (1) 
transitioning the spreadsheet to the MySQL database and (2) for refining the annotations kept in 
the MySQL database. At the first quality control checkpoint, the spreadsheet was transitioned 
into a MySQL database and inspected for mismatched, mistyped, or erroneous entries. At the 
second quality control checkpoint, the annotation terms are extensive reviewed for appropriate 
coverage and representation. We also reviewed the annotations to inspect for appropriate 
transmission of information. Wherever necessary, additional ontologies were incorporated to 
supplement the annotation terms from BAO. Table 1 displays the 37 annotations selected for 
further use, where six annotations have subset annotations. 
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Table 1: The 37 annotations used and the short description of the concepts they capture 
Annotation name Short description of the annotation 
assay source name a short name for the entity that conducted the assay 
assay source long name the long name for the entity that conducted the assay 
assay name a short name for the assay 
assay component name a short name containing the assay and its component readout 
assay component endpoint name a short name containing the assay, the component readout, and the analysis applied 
timepoint hr the duration length to conduct the test portion of the assay 
organism id the NCBI taxonomy id for the organism or cellular derivative used for the assay 
organism* the organism related to the target of the assay 
tissue the organ-level, anatomical entity of the protein or cell used in the assay 
cell format the cellular or subcellular format of the assay 
cell free component source the cellular or sample tissue source of the assayed gene protein 
cell short name the name of the cell line or primary cell used 
cell growth mode* the growth mode of a cell line 
assay footprint the physical format, such as plate density, in which an assay is performed 
assay format type* ¥ the conceptual biological and/or chemical features of the assay system 
content readout type* the throughput and information content generated 
assay design type* ¥ the method that a biological or physical process is translated into a detectable signal 
detection technology type ¥ the type of detection signal  
detection technology the name of the detection technology method 
key positive control the designated positive control  
dilution solvent the solvent used as the negative control and to make the test chemical soluble 
dilution solvent percent max the maximal amount of the dilution solvent that could be present during an assay 
key assay reagent type the type of key determinant substance of the assay 
key assay reagent the name of the key determinant substance of the assay 
assay function type the purpose of the analyzed readout in relation to others from the same assay 
biological process target the biological process or processes investigated by the assay 
normalized data type the fold induction or percent activity scale in which the assay data is displayed 
signal direction type the expected direction of the detected signal in relation to the negative control 
analysis direction the analyzed positive (upward) or negative (downward) direction 
signal direction the direction observed of the detected signal in relation to what was expected of it 
technological target type ¥ the measured chemical, molecular, cellular, or anatomical entity 
technological target gene id the Entrez gene ID for the molecular target measured by the assay 
technological target gene symbol the Entrez gene symbol for the molecular target measured by the assay 
intended target type ¥ the objective chemical, molecular, cellular, pathway or anatomical entity 
intended target gene id the Entrez gene ID for the molecular target that is the objective of the assay 
intended target gene symbol the Entrez gene symbol for the molecular target that is the objective of the assay 
intended target family ¥ the target family of the objective target for the assay 
Culture or Assay the culture or assay condition for reagent annotations 
Reagent Name Value type the type of substance or function served by the reagent 
Reagent Name Value the name of the reagent 
* The descriptions are borrowed in part from the BAO definitions; ¥ Has an annotation to describe a subset 
 
Standardized Vocabulary for Annotation 
BAO is the principle source of annotation terms. Additional ontologies were used to 
standardize and expand certain annotations for broader representation of annotation terms. The 
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NCBI Organismal Classifications (NCBI Taxon), an ontology for species taxonomy, was used 
for the organism and organism id annotations. To standardize the cell short name annotation 
terms, the Cell Line Ontology (CLO), an ontology for cell line information, was used for ‘cell 
line’ cell format (e.g. ‘CHO-K1’ is the more commonly used derivative of Chinese Hamster 
Ovaries) (Sarntivijai et al. 2011), while Cell Ontology (CL), an ontology for in vivo cell types, 
was used for ‘primary cell’ or ‘primary cell co-culture’ cell format (e.g. ‘umbilical vein 
endothelium’ is the annotation term for what is more commonly referred to HUVEC cells) 
(Meehan et al. 2011). In this way, we can identify higher level anatomical entities that the 
annotation terms may belong to (e.g. ‘brain’ tissue includes ‘Rat forebrain’, ‘Rat cortical 
membranes’, ‘KAN-TS cells’ and ‘Bovine hippocampal membranes’). 
While this is not an ontology, the NCBI Entrez Gene annotation files for human, rat, 
mouse, and bovine were used to annotate gene symbols and gene ids for the 
technological_target_gene_id, technological_target_gene_symbol, intended_target_gene_id, and 
intended_target_gene_symbol annotations (Maglott et al. 2011). 
The organism and organism id annotations are generally annotated according to the cell 
short name. In an assay performed in a cell-based format, the general understanding is that the 
host cell will have cellular machinery that influences the gene and outcome of the assay. The 
exception is given to assays performed in a cell-free format, where genes are transfected into 
expression vehicles, extracted, and used in assays without additional cellular component. In that 
situation, the organism is annotated with reference to the gene’s species of origin.  
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Modifications to annotations and annotation terms 
From the BAO framework, the assay format concept was reorganized and separated into 
two annotations, assay format type and cell format. Assay format type identifies the overall 
chemical-feature or biological-response being investigated as ‘biochemical’, ‘physicochemical’, 
‘cell-based’, or ‘whole organism’ (Vempati and Schürer 2004). The cell format type adds 
resolution to the assay format type by represents the cells as immortalized cell lines or primary 
cells, and whether they are treated as homogenous cultures, heterogeneous co-cultures, or cell-
free extracts during the course of the assay. 
Two reporter types were added to the assay design type annotation terms. The 
‘background reporter’ was introduced as a reporter type for baseline noise, while the ‘growth 
reporter’ characterizes assays that measure cellular development without intracellular or 
extracellular morphological endpoints. 
To make the assay protocol information transparent, a few annotations are devoted to 
capturing these details for reporting purposes. At present, due to the lack of formal annotation 
terms for reagent materials, the reagent name value uses unstructured text. However, the reagent 
name value type contains 32 possible annotation terms to annotate the base medium, serum 
variety, culture or assay duration, additional reagent types (e.g. antibody, extractor, fixing agent, 
or stain), environmental factors (e.g. pH level and temperature), and the expected number of cells 
in the well by the beginning of the assay. Since the assay is influenced by the preparatory 
protocols during cell culturing and conditioning, the annotation separates the reagents used for 
the preparatory, cell ‘culturing’ conditions from the experimental, ‘assay’ conditions. If it is 
applicable to the readout, key reagents are highlighted as a separate annotation. 
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Within the BAO version 1.6 framework, the ‘molecular targets’ was a branch of the meta 
targets concept. Here, the annotation terms in the ‘molecular targets’ was used as the basis for 
the target type annotations—technological target type and intended target type—and their 
subtype annotations. The difference between these two annotations is displayed in Table 1.  
‘Chemical’, ‘cellular’, and ‘pathway’ annotation terms were added to the target type 
annotation. Specifically, the ‘chemical’-type targets were given the subtypes ‘physical feature’, 
‘ATP’, or a hormone chemical name (e.g. ‘Cortisol’, ‘Corticosterone’, or ‘Estrone’). “Cellular”-
type targets can be given to scenarios where the focus is a morphology or function, so the 
subtypes may include the “cellular” or a subcellular object (e.g. mitochondria, nucleus, or 
lysosome). For ‘protein’-type targets, the subtypes ‘protein-specified’ was included for targets 
where the gene protein is known but not pursued for a certain function (e.g. not functioning for 
‘enzyme’-substrate or ‘receptor’-ligand reactions). Furthermore, ‘protein-unspecified’ was 
included for targets that non-specifically tagged proteins. Similarly, ‘pathway’-type targets and 
the ‘pathway-specified’ subtype was introduced as an annotation term for assays that probed 
known gene-mediated biological pathway, such as assays screening for estrogen receptor-alpha 
agonists. 
Visualization Software and Data Analysis 
NCBO BioPortal is a website used as the main source for viewing different ontologies 
and how they map to other ontologies, and to download archived ontology files. In addition, 
Protégé, an open-source software, was used to view web ontology language (owl) format files 
and for conducting SPARQL queries. Cytoscape, an open-source software platform for 
visualizing and integrating complex networks, was used to website were used. R statistical 
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software was used to read-in and rearrange data files, and to perform the principle components 
analysis using the prcomp function from the R Statistical library. 
Figure 2: PCA workflow of the chemical screening data 
 
A principle components analysis (PCA) was conducted to investigate the variances 
observed in the High-Throughput Chemical Screening Data from ToxCast & Tox21 (December 
2013) with regards to the ToxCast Assay Annotations, shown in Figure 2. 50% of Maximal 
Activity Concentration (AC50) values were obtained for each chemical and assay component 
endpoint pair. Using R statistical software, these values were filtered for assays with at least one 
chemical hit (i.e. values not equal to ‘100000’ or ‘NA’), then they were divided by 100000 and 
negative log transformed. Moreover, we removed the APR_1hr assays (n=20 assay component 
endpoints), which were discontinued after Phase I testing, and the BSK_SM3C assay (n=28 
assay component endpoints), which had undergone a name change to BSK_CASM3C prefix 
between phases. Next, an assay annotation binary table was generated to show mapping between 
assay component endpoints and annotation terms. Reagent information and assay identification 
annotations aside from the assay component endpoint were excluded. The log-AC50 values then 
were merged with this Assay Annotation binary table, and filtered to retain only the annotation 
terms mapped with at least one assay component endpoint in use (i.e. the column sum of each 
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annotation term is at least 1). The log-AC50 values were then aggregated by each annotation 
term, and NA or NaN data on each row (annotation term) were normalized to the mean of the 
numeric values. The data were then processed using the prcomp function and the loadings were 
visualized using the heatmap.2 function from the gplot library. The R script is displayed as 
Appendix 3. 
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Chapter 4 
Results 
Assay Annotation Structure 
The ToxCast Assay Annotation structured the 37 annotations adopted from the BAO 
framework and used them to capture annotations for 795 ToxCast assay component endpoints. 
The annotation structure follows the four sets of information and progresses from the ‘assay’ 
level to the ‘assay component endpoint’ level (Figure 1). Used to describe HTS assays, the 
primary goal of this thesis is to establish a structured annotation scheme that uses ontology-based 
annotation terms as controlled vocabulary, where applicable. In addition, these annotations can 
be used to understand general trends observable among the annotated HTS assays as well as 
explain variances observed among the screening data. 
The annotation structure displays dependencies between annotations that follow the same 
concepts. Solid arrows are depicted for relationships between annotations where one annotation 
term influences the next. As seen between the intended target type and intended target family, 
‘protein’ or ‘pathway’ intended target types would merit the intended target family to be 
annotated with a gene family; when the intended target type is ‘cellular’, the intended target 
family may be a ‘cell cycle’ or ‘cell morphology’ annotation term to follow suit. Alternatively, 
annotations linked by dashed arrows suggest a conditional relationship. If given certain 
annotation terms, the subsequent annotations may or may not be annotated. For instance, for an 
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Figure 3: The annotation structure. The annotations can be grouped into A) assay identification information, B) design information, 
C) target information, and D) analysis information. Relationships between annotations are either one-to-many (solid arrow) or 
conditional (dashed arrows), where certain dependencies may not be applicable.
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assay that uses ‘primary cell co-culture’ cell format, it is unnecessary to annotate the cell-free 
component source. In that situation, the cell-free component source get default values equal to 
NA or 0, if the annotation is numeric. In another example, for a ‘cellular’ intended target type, it 
may be unnecessary to annotate target gene symbol or gene id, so both are defaulted. The use of 
dashed arrows is a reflection that different assay technologies may have minimum information 
standards that may be seen as inapplicable with each other. 
Assay Identification Annotation 
Kavlock et al. (2012) reports the general study designs, technologies applied, and unique 
features from each Assay Source. Here, after controlling vocabulary used across Assay Sources, 
Table 2 reflects that total unique features per Assay source with reference to each level. Using 
the 795 ToxCast assay component endpoints library found to have complete ToxCast Phase I and 
II chemical screening data, the analyzed data were linked back to 541 unique assay components, 
which were generated from 328 assays (Table 2). Over 23,000 annotation terms have been 
annotated across the 26 design and analysis information annotations for these 795 assay 
component endpoints. For their respective assays, there are roughly 2,800 records for reagents 
and testing protocol information (approximately 8,400 annotation terms as both structured and 
unstructured text), and about 1,400 records for target information (approximately 7,000 
annotation terms). 
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Table 2: Assay information and content readout types 
    
Content readout type 
Assay  
Source  
Assay 
Assay 
Component 
Assay Component 
Endpoint 
Single Multiplexed 
ACEA  1 1 2 • 
 Apredica (APR) 2 20 40 
 
• 
Attagene (ATG) 2 82 82 
 
• 
Bioseek (BSK) 8 87 174 
 
• 
NovaScreen (NVS) 276 276 422 • 
 Odyssey Thera (OT) 20 20 20 • 
 Tox21 19 55 55 • 
 
 
328 541 795 
   
The assay component is meant to normalize single versus multiplexed/multiparametric 
assays according to individual readouts. Depending on the content readout type, the number of 
targets that a single experiment can probe is analogous to the number of assay components 
deriving from the same assay. At present, the ToxCast assays seem to trend as single or 
multiplexed. Shown in Table 2, NVS and OT assays are found to be characteristic single-readout 
assays displaying equal assay to assay component counts. In contrast, ATG, APR, and BSK are 
multiplexed-readout assays that measure a battery of individual targets including some that serve 
as background detection or as a measure of viability. NVS accounts for the highest number of 
assays, assay components, and assay component endpoints, while ATG assays account for the 
highest number of assay component endpoints per assay conducted. 
Some assays do not follow strictly to the conventions of content readout type but provide 
interesting variants of the single-readout type. The ACEA assay only generates a single readout; 
however, the upward and downward curve-fit analysis can yield findings for two different 
intended targets. The cell line used by the ACEA_T47D assay is sensitive to estrogen-receptor 
(ER) agonists, and can be used to detect ER-pathway-mediated cell proliferation, when analyzed 
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in the ‘gain’ of signal direction, while serving a cell viability purpose in the ‘loss’ of signal 
direction. Similarly, Tox21 assays are meant to generate a ratio to represent the pattern of 
activity. This is seen first as background and raw readout (i.e. Channel 1 and 2 wavelength 
measurements), and a viability readouts. The ratio can be calculated as a ratio of Channel 
2/Channel 1 readouts, and the viability readouts could then be used to inspect for possible 
artifacts or excessive cytotoxicity affecting the quality of the readouts. 
Assay Design Annotation 
The assay design type and detection technology type annotates the objective of the 
measurement and the method of collecting quantified data. A majority of ToxCast assays were 
found to be ‘binding reporter’, ‘enzyme reporter’ or ‘inducible reporter’ assay design types 
(Table 3). These reporter types assess different facets of how chemicals may affect genes of 
concern. 
Table 3: Assay design types annotated to ToxCast Assay Components Endpoints 
  
Totals  Assay Sources  
   
ACEA APR ATG BSK NVS OT Tox21 
Assay design type  subtype  
        Binding reporter  ELISA  149 0 0 0 148 1 0 0 
 
Fluorescent polarization  1 0 0 0 0 1 0 0 
 
Protein fragment complementation  14  0 0 0 0 0 14 0 
 
Radioligand binding  120 0 0 0 0 120 0 0 
 
FRET  8 0 0 0 0 8 0 0 
Conformation reporter  Protein conformation  4 0 4 0 0 0 0 0 
Enzyme reporter Enzyme activity  296 0 4 0 0 292 0 0 
Inducible reporter  Beta lactamase induction  7 0 0 0 0 0 0 7 
 
Luciferase induction  13 0 0 0 0 0 4 9 
 
mRNA induction  84 0 0 82 0 0 0 2 
 
Fluorescent protein induction  2 0 0 0 0 0 2 0 
Growth reporter  Real-time cell-growth kinetics  2 2 0 0 0 0 0 0 
Morphology reporter  Cell phenotype  18 0 16 0 2 0 0 0 
Membrane potential reporter  Dye binding  5 0 4 0 0 0 0 1 
Viability reporter  Cell number  4 0 4 0 0 0 0 0 
 
DNA content  8 0 8 0 0 0 0 0 
 
ATP content  10 0 0 0 0 0 0 10 
 
Protein content  24 0 0 0 24 0 0 0 
Background reporter  Artifact detection  26 0 0 0 0 0 0 26 
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Some assay component endpoints such as BSK_3C_IL8_down are binding reporters by 
way of ELISA immunoassay systems, which assess target protein expression levels (i.e. 
decreases in IL8). In contrast, NVS_ADME_hCYP1A1_Activator considers how the gene 
protein’s normal enzyme-substrate functions get affected by chemical competitive or inhibitory 
action; in this case, it assesses the level by which the enzyme-substrate functions increases. 
While inducible reporters may vary, some like OT_AR_ARE_LUC_Agonist_1440 use 
transfected firefly luciferase to probe the level of transcriptional induction.  
In addition, APR and Tox21 assays were found to have made use of ‘conformation 
reporters’, ‘enzyme reporters’, ‘morphology reporters’, ‘membrane potential reporters’, ‘viability 
reporters‘, and ‘background reporters’. This identifies that certain assay design type may be 
specific to certain assay technologies or methodologies. 
Most ToxCast assays use ‘fluorescence’ or ‘radiometry’ detection technology types 
(Table 4). ‘Fluorescence intensity’ is often the method of quantification for ‘fluorescence’-type 
assays, which are observed in assays from all assay sources except ACEA. For assay component 
endpoints associable to ‘radiometry’-type detection technology, ‘scintillation counting’ is often 
the method of choice for radioligand binding assays, found here to be specific to NVS assays. 
Though in low presence, ‘label-free technologies’, ‘luminescence’, ‘microscopy’, and 
‘spectrophotometry’ detection technology type annotation terms were annotated for at least one 
ToxCast assay component endpoints.  
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Table 4: Detection technology types annotated to ToxCast Assay Components Endpoints 
  
Totals  Assay Sources  
   
ACEA APR ATG BSK NVS OT Tox21 
Detection technology  
type subtype 
        Fluorescence  Fluorescence intensity  582 0 40 82 148 260 14 38 
 
Fluorescence other  1 0 0 0 0 1 0 0 
 
FRET: TR-FRET  8 0 0 0 0 8 0 0 
Label Free Technology  Electrical Sensor: Impedance  2 2 0 0 0 0 0 0 
Luminescence Bioluminescence 21 0 0 0 0 0 4 17 
 
Chemiluminescence 1 0 0 0 0 1 0 0 
Microscopy  Optical microscopy: Fluorescence microscopy  4 0 0 0 2 0 2 0 
Radiometry  Scintillation counting  136 0 0 0 0 136 0 0 
Spectrophotometry  Absorbance  40 0 0 0 24 16 0 0 
 
 
Table 5: A comparison of the assay design subtypes by the detection technology subtypes 
  
Detection technology subtypes 
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Assay design subtypes No of assay component endpoints 594 136 40 21 8 4 2 1 1 
enzyme activity 296 264 16 16 0 0 0 0 0 0 
immunoassay: elisa 149 148 0 0 0 0 0 0 0 1 
radioligand binding 120 0 120 0 0 0 0 0 0 0 
mRNA induction 84 84 0 0 0 0 0 0 0 0 
cell phenotype 26 24 0 0 0 0 2 0 0 0 
protein content 24 0 0 24 0 0 0 0 0 0 
artifact detection 20 20 0 0 0 0 0 0 0 0 
protein fragment complementation assay 14 14 0 0 0 0 0 0 0 0 
luciferase induction 13 0 0 0 13 0 0 0 0 0 
DNA content 12 12 0 0 0 0 0 0 0 0 
ATP content 10 2 0 0 8 0 0 0 0 0 
FRET 8 0 0 0 0 8 0 0 0 0 
beta lactamase induction 7 7 0 0 0 0 0 0 0 0 
dye binding 7 7 0 0 0 0 0 0 0 0 
cell number 6 6 0 0 0 0 0 0 0 0 
protein 6 6 0 0 0 0 0 0 0 0 
fluorescent protein induction 2 0 0 0 0 0 2 0 0 0 
real-time cell-growth kinetics 2 0 0 0 0 0 0 2 0 0 
fluorescent polarization 1 0 0 0 0 0 0 0 1 0 
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A comparison between the two annotations suggests that the same detection technology 
type may assess different assay design types; conversely, the same assay design type may be 
assessed by different detection technology types (Table 5). It is noteworthy to mention 
‘fluorescence’ detection technology type, which have been applied to all assay design types 
except ‘growth reporters‘, reflects that fluorescent protein and probe technologies have 
developed in greater extents for HTS targeted measurements compared with other technologies. 
Related to the detection technology, it was found that the reagent and experimental 
components annotations come secondary to the format annotations. We attempted to capture the 
conditions of the test environment, but in doing so found that separate protocols are used for 
preparations prior to the assay (the culture conditions) compared to the actual assay. Shown in 
Table 6 is an example of the reagent information for the APR_HepG2_1hr assay. Under the 
Culture and Assay conditions, we display the types of reagent of condition used (left) and the 
name or value to that reagent or condition (right). Table 6 is somewhat representative of the cell-
based high-content screening assays, as opposed to cell-free biochemical assays which are only 
annotated with assay conditions.  
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Table 6: Reagent and components information for the APR_HepG2_1hr assay 
 
In addition, depending on the assay, if a reagent is the key factor(s) towards quantifying 
signal changes, then the reagent(s) would also be annotated as the key assay reagent, an 
annotation of the assay component level. Generally, this means that the reagent is captured as a 
factor of the ‘assay’ conditions. Taking the APR_HepG2_1hr reagents, the MitoTracker Red 
(stain) is necessary for identifying the mitochondria within each cell, and so it is highlighted as 
the key assay reagent for APR_MitoMembPot_1hr and APR_MitoMass_1hr assay components. 
However, like for ATG CIS and TRANS assays, specific reporter transcription unit (RTU) used 
during the cell-culturing preparatory protocols are central towards the reporting of the respective 
readouts. Moreover, it is worthy to mention that label-free technologies, such as the cell 
electrical sensing used for the ACEA_T47D assay, would not have a key assay reagent. 
While the connections could not be displayed in Figure 3, the assay format type and the 
cell format, and in some instances the cell short name, have a predominant influence upon the 
reagent use. Certain reagents are necessary for the culture of cell-based versus biochemical assay 
Culture Assay 
media_base 
Eagle's minimum essential media/ 
Earle's balanced salt solution 
media_base 
Eagle's minimum essential media/ 
Earle's balanced salt solution 
media_serum 10% FBS media_serum 10% FBS 
cofactor non-essential amino acids extracellular matrix rat tail collagen I 
cofactor glutamine buffer Hank's balanced salt solution 
inhibitor penicillin fixing agent 3.7% formaldehyde 
inhibitor streptomycin antibody primary antibodies 
media_temp_celcius 37 stain Hoechst-33342 dye 
media_time_hr_min 18 antibody anti-phospho-histone-H2AX antibody 
media_time_hr_max 24 antibody anti-a-tubulin antibody 
media_cell_aliquot 4200 antibody anti-p53 antibody 
    stain MitoTracker Red 
    antibody anti-phospho-c-jun antibody 
  
antibody anti-phospho-histone-H3 antibody 
  
media_temp_celcius_min 25 
  
media_temp_celcius_max 37 
    media_time_hr 1 
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format types. The same is observed for assays that use ‘primary cells’ or ‘primary cell co-
cultures’ versus ‘cell lines’. Certain cell lines will have more specific media and serum 
specifications than others. Table 7 provides a short summary of the three most commonly used 
organism and tissue types by each assay source, and how many unique cell short names or cell 
free component source used by each assay source were annotated to one of five possible cell 
format types. 
Table 7: Organism/tissue types and cell format types  
 
ACEA APR ATG BSK NVS OT Tox21 
Unique Organism & Tissue-types  1 1 1 3 30 5 6 
Most frequently used human  
(breast) 
human  
(liver) 
human  
(liver) 
human  
(vascular) 
human  
(recombinant)
¥
  
human  
(kidney) 
human  
(kidney) 
2nd most frequent       human  
(skin) 
rat 
(brain) 
Chinese hamster 
(ovary) 
human  
(breast) 
3rd most frequent       human  
(lung) 
rat  
(recombinant)
¥
  
human  
(cervix) 
human  
(liver) 
Cell format types 
       cell line 1  3  2  0 0 20  19  
primary cell 0 0 0 4 0 0 0 
primary cell co-culture 0  0  0  4 0  0 0  
cell-free 0 0 0 0 188  0 0 
tissue-based cell-free 0 0 0 0 88  0 0 
¥ 
Target gene proteins were extracted from expression vehicles (e.g. insect cells, bacterial, or cell lines) 
 
Target information 
The names of the ToxCast assay component endpoints may not immediately focus on the 
intended target. In fact, with just the assay component endpoints alone, it will be a challenge to 
determine what the targets are at all. The intended target is the objective probe of the chemical 
bioassay, and it can often be said to be the center of communication in regards to the chemical’s 
activity. This can discount the value of the technological target. After all, the intended target is 
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measured either directly or through an interpretation that uses the technological target. The 
current annotation uses technological target type, intended target type, biological process target, 
intended target family type and gene annotations to distinguish these different motifs. 
Across the 795 ToxCast assay component endpoints, by gene ID and target type 
combinations, there are 383 unique technological targets and 387 unique intended targets. The 
technological target types range from ‘DNA’, ‘RNA’, ‘protein’, ‘cellular’ and ‘chemical’ types, 
while the intended targets include ‘protein’, ‘cellular’, ‘pathway’, and ‘chemical’ types. Though 
it may be simplest to annotate one target per assay, this approach overlooks the value in 
multiplexed assay readouts. The technological and intended target annotations were created to 
dissociate assays that use different means to measure the same intended target. 
A comparison of the technological and intended targets shows that some assays make 
direct measurements, while others use the technological target as a quantifiable surrogate for the 
intended target. Table 8 summarizes the occurrence of these measurement relationships with 
regards to the target types from each assay source. Assays that make direct measurements have 
the same annotations for technological and intended target types and gene ids. Alternatively, 
assays may make use of technological targets as quantifiable surrogates or close substitutes to 
approximate the intended target, shown boxed in Table 8. 
 Table 8: Comparison of technological and intended target types
 
ACEA  APR BSK  Tox21  ATG  BSK  NVS  Tox21  ACEA  APR  OT  Tox21  
Intended  cellular  protein pathway  chemical  
Technological  
            cellular (25)  1 8
 
 12  3  0  0 0 0 1  0 0  0 
protein (662)  0 4  8
 
 0  0  154  422  24  0 16 34  0 
RNA (138)  0 0 0 0  138
 
 0  0  0  0 0 0 0 
DNA (12)  0 8  0 0  0  0  0  0  0 4  0 0  
chemical (22)  0 0 0 10  0  0  0  0  0  0  0  12  
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Most of the ToxCast HTS assays are straight-forward technologies that make direct 
measurements. Displayed in Table 8 as the unboxed values, there are 24 ‘cellular’, 600 ‘protein’, 
and 12 ‘chemical’ targets directly measured by an assay component endpoint from each assay 
source. For example, the BSK ELISA-based assays (e.g. BSK_3C_MIG_dn) use protein-specific 
antibodies to bind to specific target genes. The change in fluorescence would be directly relative 
to the protein expression level at each concentration tested. In a similar way, the Tox21 
autofluorescence assays (e.g. Tox21_Autofluor_HEPG2_Cell_green) aim to detect inherent 
fluorescent properties from the test substance. These assays probe different color wavelengths to 
observe baseline changes that could be concentration-dependent artifact fluorescence from the 
chemical. 
Alternatively, assays may target an abstract component of the intended target’s biology as 
a function of the technological target. Shown in Table 8 as boxed values, there are 30 ‘cellular’, 
138 ‘protein’, and 55 ‘pathway’ targets assessed by various methods and technological target 
types. For instance, OT_PPARg_PPARgSRC1_0480 measures the fluorescence generated from 
the complementary binding of human peroxisome proliferator-activated receptor gamma (gene 
symbol: PPARG, gene ID: 5468) with the v-src kinase (gene symbol: SRC, gene ID: 6714). 
Changes in the measured level of fluorescence and relative localization within the cell are 
indicative of changes along the PPARG signaling pathway. For assays where the concept 
becomes too complex to represent by target type and gene annotations alone, the biological 
process target would be annotated. Take ATG_PPRE_CIS for example. human Peroxisome 
Proliferator-Activated Receptor Alpha, Delta and Gamma—PPARA (gene ID: 5465), PPARD 
(gene ID: 5467), and PPARG (gene ID: 5468), respectively—are the technological targets 
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measured together as a unit as downstream products of transcription factors binding to the 
Peroxisome Proliferator-activated Response Element (PPRE). Changes to the mRNA levels of 
these target genes reflect chemical effect to the upstream transcriptional events, so the biological 
process target is the ‘regulation of the transcription factor activity’. 
Furthermore, to represent a complex signaling or regulatory pathway as the assay target, 
the biological process target is used in conjunction with reference gene focal to that pathway. 
For instance, the ACEA assay monitors cellular growth kinetics as an indication of cytotoxicity 
or estrogen receptor alpha (ESR1) signaling for cell proliferation. Respectively, the cytotoxicity 
intention has a ‘cellular’ intended target type and ‘cell cycle’- ‘cytotoxicity’ intended target 
family. The cell proliferation intention has ‘pathway’ intended target type, ESR1 as the intended 
target gene symbol, ‘nuclear receptor’ and ‘steroidal’ as the intended target family, and 
‘regulation of cell proliferation’ as the biological process target. 
To group the 387 unique intended targets, we developed 24 intended target families (84 
subfamilies). Figure 4 is a simple connection map displaying the intended target families to their 
intended target subfamilies, sized by the number of times an intended target gene is mapped to 
those annotation terms. Three main categories currently exist in the intended target families: 2 
cellular aspects (i.e. ‘cell cycle’ or ‘cell morphology’), 21 gene families (e.g. ‘GPCR,’ ‘kinase,’ 
or ‘protease’), and one for quality control aspects (i.e. background measurements), shown in 
Appendix 1. The intended target families have one-to-many relationships with the intended 
target genes, providing a means to filter down to the targets of interest or to query for assay 
identifiers associated within the intended target family groupings.
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Figure 4: Intended target family annotation terms
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The structure to the intended target families is a work-in-progress that attempts to pull in 
groupings from various ontology sources. First, we realize that gene protein vocabulary bear 
intricate connections in terms of the active/inactive sequence domains, functions, and 
relationships between superfamily, family, subfamily and many more categories. These 
categories are often unevenly distributed between categories making it difficult to communicate 
as some are more developed than others. For the majority of gene proteins, groupings are formed 
based on function and similarity in protein sequence. Some groupings are under debate as more 
gene proteins are characterized and the functions annotated. The intended target families and 
intended target subfamilies are over-simplifications; they are an attempt to cross-sectionally 
group the target genes within reason by their first and second order associations. Often, this 
means the gene-oriented intended target families are the class of proteins, and the intended target 
subfamilies are actually the regarded superfamilies under that class. 
From same creators as BAO, the G-Protein Coupled Receptors Ontology (BAO-GPCR) 
was used to define the high-leveled subfamilies within the domain of G-protein coupled 
receptors (GPCRs) (Przydzial et al. 2013). Unfortunately, for most of the other gene-oriented 
intended target families, there is not a single well established and publicly ontology to represent 
each topic area. This can be seen with the kinase family, which continues to have new gene 
proteins discovered and new subfamilies introduced; thereby, older classifications are antiquated 
and new introductions are not well-characterized (Manning et al. 2002). The five intended target 
subfamilies for kinases displayed are a product between the schemes used in the KinaseDB, the 
WikiKinome, National Cancer Institute Thesaurus (NCIT) and Medical Subject Headings 
(MeSH). The same can be said for the ‘Protease’, ‘Phosphatase’, and many other gene-oriented 
intended target families. 
36 
 
When mapped out, we found that 62 intended target gene symbols have homologs genes 
investigated within ToxCast. These gene symbols were mapped back to 145 assay component 
endpoints that could be used for comparison of orthogonal assays (see Appendix 2), excluding 
those genes that were mapped to only one assay component. These genes belong to the ‘nuclear 
receptor’, ‘dna binding’, ‘growth factor’, ‘protease’, ‘cyp’, ‘esterase’, ‘gpcr’, ‘ion channel’, and 
transporter intended target families. Furthermore, among these identified assay component 
endpoints, 24 non-human genes investigated by NVS cell-free protein-binding assays have a 
human homolog investigated among the rest of the identified 145 assay component endpoints. 
These assay component endpoints open the possibilities to compare orthogonal assays for 
understanding different chemical interaction patterns and for comparisons across different 
species.  
Assay Analysis Information 
Assay component endpoints distinguish the data processing decisions applied unto the 
raw assay component data, represented in Figure 4 by four annotations. Differences in the 
concepts covered in these annotations are represented in Table 1. The normalized data type 
prominently observed in ToxCast assay component endpoints is ‘percent change’. Subsets of 
ATG (n=80) and BSK (n=174) assay component endpoints are annotated as ‘fold induction’ 
type. ‘Fold induction’ normalization uses the performance of the negative control as the baseline 
reference, while ‘percent change’ uses the performance of negative control as the baseline and 
positive control for normalizing the maximal activity. The analysis direction details whether the 
assay component data were fitted in a ‘positive’ or ‘negative’ activity direction, important 
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concepts when using values generated, such as the lowest effective concentration (LEC) and the 
activity scores (e.g. AC50). 
The data analysis was used to also identify findings that are both expected and 
unexpected of the assay component. With respect to increasing test chemical concentrations, the 
signal direction type annotates whether the raw readout is expected to have a ‘gain’ or ‘loss’ in 
signal activity relative to that of the negative control, may go ‘both’ ways, or where the 
expectation is no change (‘none’). The actual analysis applied is described by the analysis 
direction, annotated as either ‘positive’ or ‘negative’.  
For assay component endpoints with theoretical intents (i.e. signal direction type: ‘gain’ 
and ‘loss’), the signal direction is annotated as ‘gain’ if the analysis direction annotation 
corresponds (i.e., ‘positive’) or as ‘loss’ if they do not correspond (i.e. ‘negative’). For example, 
the NVS_ADME_hCYP1A1_Activator is expected to have a ‘loss’ of signal (signal direction 
type) as increasing chemical concentrations impedes the cell-free reaction. However, it is fitted 
in the ‘negative’ analysis direction, indicating that a decrease in the fluorescent substrate 
presence (the reaction was promoted to generate the product) relative to the negative control was 
detected with increasing test concentrations. Chemicals active in this assay component endpoint 
would, therefore, have caused a ‘gain’ in the protein’s activity (signal direction). 
For signal direction types annotated as ‘both’ or ‘none’, there was not a theoretically 
intended direction. In these cases, the signal direction only corresponds to the analysis direction, 
where ‘positive’ yields ‘gain’ and ‘negative’ yields ‘loss’, respectively. 
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Principle Component Analysis 
With the December 2013 ToxCast Phase II Data Release, there are 795 assay component 
endpoints with complete chemical screening data. After generating the binary file to map each 
assay component endpoint to their annotation terms (data not shown), we used the global PCA 
using 1,039 of the annotation terms. These terms come from all annotations, except the assay 
identification annotations (removed as non-descriptive annotation terms) and the reagent and 
experimental components annotations (had not undergone full quality control review). The PCA 
produced 1,039 principle components with loading values for each annotation term at each 
principle component (correlation values to each principle component). Figure 5 displays a heat 
map of PC1 through PC5 with the clustered annotation terms, where the loading values are 
presented as heat between dodger blue (negative value) to orange (positive value). 
Figure 5: Heat map of the PCA loadings clustered by the annotation terms for the first five 
principle components 
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The percent proportion of variance for the first three principle components is about 33%, 
where PC1 alone can explain about 20.2% of the variance observed across the screening data. 
This is not unexpected since the percent proportion for each principle component continues to 
decrease as it approaches PC1039, where the summation of all principle component percent 
proportions approaches 100%. Our findings suggest that this global PCA cannot explain the 
variability very well. However, it does help identify the conceptual clusters of annotations terms 
contributing to each of the principle components (Figure 5, at right). For instance, for PC1, we 
observed extreme heat or correlation values coming from a number annotation terms related to 
stress on the test environment and contributors to promiscuous activity. This includes but is not 
limited to factors of the technology, assay and cell format, and where the target of interest is 
cytotoxicity or cellular stress. These peripheral factors to an assay are potentially the main 
contributors to noise in the data and that this may interfere with the cell-free as well as cell-based 
assays.  
Continuing along the principle components, there seems to be certain cluster of 
annotations contributing to more variance than others. Along the right side of Figure 5, 
phosphatases and kinases were identified as next most predominant factor contributing to 
variability in the screening data (PC2), followed by GPCRs, ion channel proteins, and 
transporters (PC3), then CYP enzymes (PC4), and steroidal nuclear receptors and a number of 
transcription factors (PC5). Assays that have these features or combinations of these features 
may be more prone to promiscuous hits that others. What this calls for is new analytical 
approaches to adjust or further analyze these hit variance issues. 
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Chapter 5 
Discussion, Conclusions, Limitations, and Future Directions 
Discussion 
The diversity of in vitro assays has continually broadened, bringing new options for 
investigative toxicology to light while increasing the complexity and information demand. There 
was no structure to meet this information demand. In 2006, at the beginnings of ToxCast, the 
only information sources available to understand an assay and its readouts would have come 
from manuscripts, summary protocols, and other printed sources. Even then, each source may 
use different vocabulary or report different amounts of detail, making it a tedious effort to fully 
grasp one assay let along comparing between multiple, diverse assays. The situation became 
truly challenging when multiple assays of different technologies provided non-concordant results 
for the same intended target. Finally, in recent years, frameworks and minimum information 
standards have arisen. This annotation collates these recent developments and proposes a 
structured approach based on ToxCast assays to better address information capture about an 
assay and to organize them for focused communication. 
The ToxCast assay library has been annotated using a customized, systematic method for 
assay data integration and aggregation. Reflective of one of the visions from MLP, ToxCast 
Phase I and II chemical sets are tested across all 328 ToxCast assays to comprise a complete data 
matrix of comprehensive chemical-biological data (Vempati et al. 2012). We successfully 
applied this annotation approach across 328 ToxCast assays with minimal terminology additions 
to allow for rapid data processing and quality control. 
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Numerous consortia have discussed the minimum information standards appropriate for 
quality reporting. These discussions have become technology-oriented, developing specific 
standards for subsets of assay technologies (Goetz et al. 2011; Patlewicz et al. 2013). The BAO 
framework was constructed with a wide breadth of coverage, capturing the NCATS reporting 
parameters and parameters from other technologies (Sittampalam et al. 2012; Vempati et al. 
2012). Our approach applies structure to the BAO framework, where different annotations (e.g. 
content readout type, detection technology name, intended target family) may flag the use of 
certain guidelines. This unifies the annotation standards though it requires critical review of the 
annotation databases and their limitations. In the future, it may be useful to have these guidelines 
incorporated alongside the detection technology and design annotations. 
Two novel concepts were developed as a result of this study. The first concept is the 
hierarchical assignment of assay annotations as attributes of a particular level. Using the order 
displayed in Figure 3A, the lineage between an assay to the assay component endpoints can be 
defined for conventional usage. Following this example, we can communicate about ‘Bioseek’ 
(name of assay source--BSK) with an interest in the BSK_3C assay (name of the experiment). 
Among its readouts, the assay component BSK_3C_IL8 (name of the raw readout) was analyzed 
to produce the assay component endpoint BSK_3C_IL8_down (name of the analyzed readouts). 
Conversely, the assay component endpoint can be tracked back through its lineage to identify 
other assay components and assay components that may be have generated from the same 
experiment, such as BSK_3C_IL8_up.  
A similar approach is taken by the BioAssay Research Database (BARD), a collaborative 
project by MLP that also uses BAO as their foundational framework. BARD applies a higher 
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level of separation where HTS projects are broken down into experiments and further into 
individual assays. The BARD approach can be adopted into our approach. It essentially stops 
short of the assay component and assay component endpoint levels, but it is in agreement that 
annotations can be separated perspectively by level for better organization and communication. 
Secondly, the assay target annotations were developed to conceptually capture the 
technological target(s) for measurement as well as the intended objective target for assessment. 
Under the BAO framework, a subjective target needed to be selected. The vocabulary did not 
lend to separate that target as the reagent fluorescent probe or a gene of interest. Here, we use the 
key assay reagent annotation to set aside signal probes, and by taking this conceptual separation 
of technological versus intended targets a structure is established to capture targets that are more 
complex and abstract. 
The design information annotations provide context for how the target was measured. By 
simply using the target annotations to filter assays, features such as the objective and 
experimental conditions may be ignored. The study design information is the key component for 
reproducibility issues and often questioned when discussing the influencing factors. For instance, 
fluorescence screening assays are prone to artifact interference from test substances that may 
refract light. Nanomaterials, particulate matter, coloring agents, and volatile test chemicals may 
suffer from the artifact fluorescence interference as well as agglomeration and solubility issues, a 
reason for new assays to use the liquid-air interface culture technologies (Ghio et al. 2013). 
Knowing these limitations, one might say certain test substances are inapplicable to most HTS 
technologies, resonating the need for new, better assay technologies for activity testing. 
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Conclusion 
As an organization tool, we’ve shown that the ToxCast Assay Annotations follows a 
logical structure that can filter down and simplify differences between assays. Combination use 
of the annotations, as seen with assay design type and detection technology type, can enhance 
these aggregations and differentiations. Similarly, combination use of the technological and 
intended target annotations can reveal the different modes of assessing the same intended target 
using different technological means. Furthermore, to support the filtering feature, the intended 
target family annotations were introduced to guide groups of target concepts. 
A key idea generated from these results was that the annotations are indeed 
interconnected, and that these connections can help with reducing redundant annotations which 
can be grouped at a higher level. The flattened table approach for annotation, while useful for 
initial annotations, was too flat and made it difficult to convey the annotations. The annotations 
assigned to the assay component endpoint level are features that can only be separated at the 
most terminal level, whereas the annotations for the raw readouts (e.g. assay design, detection 
technology, and technological target) can be grouped up at the assay component level, and again 
for the assay level. These level groupings provide the organization necessary to concentrate the 
communication, keeping details focused on the experiment, the raw data, or the analyses 
separately. 
Ultimately, the annotations are a support tool to understand the results of the chemical 
screening data. The combined display of multiple annotations can highlight the similarities and 
differences observable in the chemical hits. The principle component analysis showed that there 
are certain annotations terms, certain features belonging to the assays, which may be associable 
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to promiscuous hits and high variance in detected hits. The primary component was isolated to 
be differences in cell sensitivity and technology factors that may add stress on the testing 
environment. Therefore, while the annotations may support informed use of the chemical 
screening data, they can be applied to identify noise that may be truly or artificially stimulated. 
Limitations and Future Directions 
We recognize that there needs to be more definition for assays that target gene or 
pathway ‘agonist’ and ‘antagonist’ activities as well as for those that don’t probe gene targets. 
Beyond the 328 assays, we also annotated over 100 pilot assays, discontinued assays, and in-
progress assays. In particular, several annotations are in-development to capture ‘antagonist’ or 
‘agonist’ target status, and to capture the agonist stimulators necessary for antagonist assays. 
Similar to the positive controls and reference chemicals used in each assay, the agonist 
stimulators were chosen from published literature and do not have clear justifications for the 
selection. As more chemical probes are discovered, this area and annotation should be further 
developed for better clarity. This also extends to metabolic and pharmacokinetics assays, which 
target certain chemical derivatives as the measure of gene-mediated biological processes. 
Furthermore, new HTS assays that target developmental endpoint currently meet certain 
limitations within our annotation approach. Many of the zebrafish assays in the public domain 
look for time-dependent developmental effects, many of which are not gene targets but are 
malformations or disease-state targets (Sipes et al. 2011; Padilla et al. 2012; Truong et al. 2014). 
One solution is to incorporate more Gene Ontology biological process and cellular component 
terms or another source for formal vocabulary on developmental effects. However, these assays 
tend to use multiparametric approaches, which there currently is no formal vocabulary set for 
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certain analytical techniques and calculations. The same can be said of stem cell and pluripotent 
cell differentiation assays. To a lesser degree, multi-cell organotypic cultures are another 
promoted area of new assay development, which can be captured using our annotation approach 
with a few minor adjustments to the assay format type and cell format annotations. 
As a byproduct of the assays that were used for annotation here, the target annotations 
have a bias towards gene-oriented assays. For cell-based assays, the targets can be generalized 
using the ‘cell cycle’ and ‘cell morphology’ intended target families. Annotation terms such as 
‘mitochondria’ and ‘nucleus’ were incorporated into the target subtypes annotations. To separate 
the assay target as an indicator for localization versus organelle disruption would require the use 
of the biological process target. This might force the use of Gene Ontology biological process 
target annotations, so new annotations might be necessary to better capture cellular targets. 
Visual mapping of cellular event pathways or adverse outcome pathways will also aid in the 
representation of ‘pathway’ target types. 
Descriptive elements of HTS assays have previously been used to aid the validation of 
assay results. Patlewicz et al. (2013) had focused on the analytical validation of the ToxCast 
Androgen Receptor (AR) assays, where differences in the human and rat cell free component 
source displayed variant binding capacities. ToxCast now includes a Chimpanzee AR binding 
assay, NVS_NR_cAR, which was compared against different AR homolog performance 
including a wild-type human AR recombinant expression in COS monkey kidney cells (Hartig et 
al. 2008). The ToxCast human AR assay uses a different AR protein extracted from LNCaP 
human Leydig cells (Knudsen et al. 2011). The utility in adding the chimpanzee AR assay is that 
it expands the detection sensitivity of perturbing the gene target across mammalian homologs 
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(Knudsen et al. 2011; Sipes et al. 2013). At the same time, it places more importance on 
annotating features of the experimental protocol to enable similar analyses to that of the AR 
assays. New annotations should be considered to capture species ‘wild-type’, ‘polymorphic or 
mutant’ gene variants, whether obtained through ‘recombinant’ expression or from ‘endogenous’ 
biological sources, or if there are other protein modifications such as ‘ligand binding domain 
only’ recombinant expression products. 
Presently, there is not a minimal way to query for supplemental parameter readouts. As 
seen in the Tox21 AR beta-lactamase assay, we observe all assay components as inducible 
reporters but some as ‘background control’ or ‘reporter gene’ assay function types. This assay 
took multiple reads through which the Tox21_AR_BLA_Agonist_ch1 readout measures the 
baseline (‘background control’) while Tox21_AR_BLA_Agonist_ch2 and 
Tox21_AR_BLA_Agonist_ratio take the differential, ‘reporter gene’ comparisons (Huang et al. 
2011). Similarly, ATG assays take reporter gene readouts (e.g. ATG_AR_TRANS), while a 
number of internal markers are used as ‘background control ‘parameters (e.g. 
ATG_GAL4_TRANS, ATG_M_06_TRANS), a common aspect of multiplexed assays 
(Romanov et al. 2008). A possible solution is to remind the user that ‘signaling’, ‘reporter gene’, 
or ‘binding’ assay component endpoints may need to be analyzed with relation to parameter 
assay component endpoints that are derived from the same assay and have ‘viability’ or 
‘background control’ assay function types. 
The ToxCast Assay Annotation is presently used to support software developments with 
assay descriptions, like for the ToxCast Dashboard. This software tool is meant to promote 
informed use of the HTS data and consistent data representation in regulatory decision making. 
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Currently, the BioPortal interface can map between ontologies by their mutual annotation terms. 
This feature opens the possibility of ontology-based data integration, linking out with external 
databases, and normalization of data format heterogeneity and semantics. Judson et al. (2012) 
has described a knowledgebase essentially as a database supported with an ontology. The 
ontology makes the database better built to conduct search options. As new technologies become 
available, incorporating new vocabulary into the existing ontologies enables a consistent means 
to update the knowledgebase. Applying these functions to the ToxCast Dashboard can greatly 
improve its usability to accommodate the clients’ work needs. 
The ‘assay component map’ is a separate table meant to map the raw data files names to 
the appropriate assay component. This is a recent development that attempts to foster the data 
analysis pipeline with the annotation resource. 
As mentioned, additional annotations are in-progress to highlight more features of an 
assay. Moving forward, the ToxCast Assay Annotation may incorporate parallel annotations to 
support a main annotation with the respective vocabulary and schema used by other ontologies in 
the same domain. For instance, the Brenda Tissue and Enzyme Source Ontology contains 
interesting annotation terms for endogenous enzyme source and anatomical entity hierarchy, 
which could be used alongside CL and CLO for cell short name annotations (Gremse et al. 
2011). Similarly, the reagent and experimental components information, presently BAO 
annotation terms are used, but the Experimental Factor Ontology carries similar annotation terms 
which could also extend to the assay format type and cell format annotations. 
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Chapter 6 
Indoor environmental health sampling, Science talk panels, and mammary gland tumor 
bioinformatics investigation: the Practicum experience with Silent Spring Institute 
 
Joining Silent Spring Institute (SSI) for a two week practicum, I had the great pleasure 
and opportunity to listen in on several of these developments, learn from their experts, and 
contribute to them a segment of database and pathway informatics. After some conversations 
with SSI Director of Research and my practicum preceptor, Ms. Ruthann Rudel, the practicum 
was initiated with three intents, each having environmental science competencies. The first was 
to shadow field scientists and observe their exposure sampling protocol, which exercise diversity 
and cultural competencies. The second was to participate in Silent Spring Institute’s scientific 
meetings and get a feel for how business and science operates in a non-government organization 
(NGO), which involve program planning discussions. The third was to work with SSI experts to 
learn about the Mammary Carcinogen Review Database, one of SSI’s product resources, and to 
use it with a bioinformatics and cheminformatics approach, an application of communication and 
informatics skills.  
Diversity and Cultural Competency 
The goal of the first intent was to demonstrate awareness of and sensitivity to the varied 
perspective, norms, and values of others based on individual and ethnic differences. This was 
done by shadowing two specialists, Mr. Oscar Zarate from SSI and Ms. Meryl Corton from 
Harvard School of Public health. The two specialists were conducting an indoor exposure 
sampling study in a newly-occupied housing-community in the Boston area. On one sampling 
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event, a sampling module was set up in the home of a native Spanish-speaking participant, so 
Mr. Zarate administered the intake survey entirely in Spanish. The survey was very extensive 
and it is important to mention the necessity of interpretive clarifications; for instance, “Number 
of chairs” versus “Number of fabric-covered chairs”, details which may be overlooked are 
separate survey questions within the intake form.  
To efficiently get through the visit in 1 hr, I assisted Ms. Corton in setting up the module, 
sample for floor dust, and conducted the walk-through inspection. The engineered module was 
equipped with different passive air badges and particulate matter collectors, and it was set up to 
sample for 1 full week at a single location within the household. Like some of the intake 
questions, the walk-through inspection was a very eye-opening exercise, requiring awareness of 
direct and indirect exposure factors that may influence the indoor air quality in each room (e.g. 
the number of air purifiers, use of aromatic candles or air fragrances, mold spots, and chipped or 
cracked paint along the infrastructure), a careful reminder of what good housekeeping would 
include and what it could prevent. 
Program Planning 
The second intent was to participate in SSI’s scientific meetings. These discussions 
identified the needs of the scientific and public community, and how to better meet these needs 
as a research entity. Some big concepts out of these meetings include consideration for who the 
proverbial stakeholders are, what it means to outreach and maintain community involvement, 
and what are the scientific products. For example, SSI has been a long-time researching entity 
for the Cape Cod, Massachusetts community. Having looked into the environmental 
contaminants, pesticides used, and the unusually high incidence of cancer and health concerns 
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from the region, what more could be done? Is the amount of research conducted sufficient? This 
resonates whether an NGO may get too niche or may have departed from specialization. This has 
implications for the scientific direction of the institute, the kind of skill sets and human resource 
to develop, and the kind of contribution and amount of people-time to spend towards a 
collaborative product. 
The scientific meetings also demonstrate collective information sharing, a 
communication competency. It was similar to an academic lab meeting, where decisions made or 
results gathered are weighed as “useful or not,” “may contribute towards policy or other 
publication products,” or whether it may be good practice to compare with a respected data 
source or review summary. Through this, scientific results may get digested when reporting out. 
Particularly when reporting to local, non-scientific communities, phrasing and semantics need to 
be considerately and sensitively applied. 
Communication and Informatics 
 Finally, the third intent involves collective information sharing, problem-solving, data 
interpretation, and considering genetic factors for adverse health outcomes. Though it was not 
able to be completed within the 2 week timeframe and follow-up developments have not been 
successful, this has been useful as a learning exercise in understanding different data resources. 
During the 2 week practicum, I was asked to present on a bioinformatics approach performed for 
a Human Leukemogen Project (Thomas et al. 2012) with the intent to do a similar analysis using 
a chemical set from the Mammary Carcinogen Review Database. This was a hypothesis 
generating exercise and an effort to identify chemical clusters based on enrichment of KEGG 
pathways. A few issues immediately surface: 1) unlike the Human leukemogens, the mammary 
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gland carcinogen chemicals are largely obtained from mouse and rat models, and it was not clear 
whether they lead to tumors of specific neoplastic or non-neoplastic types; 2) while the original 
plan was to use Comparative Toxicogenomics Database (CTD) files, the data files had missing 
and confusing data, and initial statistical approaches using Gene Set Enrichment Analysis 
(GSEA) failed to re-capitulated CTD displayed results; and 3) because the chemicals are mouse 
and rat actives, it would be important to consider enrichments of mouse and rat pathways. 
To address these bioinformatics issues, with support from Drs. Lisa Truong and Richard 
Judson from EPA NCCT and Dr. Reuben Thomas from UC Berkeley, Ms. Janet Ackerman from 
SSI and I data-mined through different chemical-biological databases. For the first issue, we 
looked into the mouse and rat pathology data in Chemical Effects in Biological Systems 
database. However, while the data is rich, it required significant computing power and re-
analysis of raw data; therefore, the tumor specificity categorizations could not be determined. 
Next, we identified that due to licensing limitations the CTD gene-pathway file was incomplete 
of certain KEGG pathways of interest and that an alternative source would be needed to consider 
the respective mouse or rat pathways. We then investigated the KEGG REST web services to 
extract pathway information, and we found that this can directly provide species-specific 
pathways, rather than conduct a gene-ortholog translation effort between species. Still, 
recapitulating the pathway enrichments failed; we discovered that CTD takes a human-health 
oriented approach so only human pathway enrichments would be displayed. Therefore, there is a 
need for more inter-species genetic and physiologic research to better understand the 
mechanisms of toxicity specificity and differences in susceptibility for translational science. 
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In addition, within the CTD chemical-gene interaction data set, it was discovered that 
transgenic studies make up a large proportion of the available mouse and rat data subsets (e.g. 
while the tested organism was a mouse species, the genes assessed are inserted from the human 
genome). These data sets have been corrected for using NCBI files for the respective rat, mouse 
and human genomes and will be re-run for enrichment patterns in the near future. This did, 
however, identify that rat and mouse chemical-gene data is actually very meager for the 273 
chemicals of interest (800-1200 interactions in rat; 4000-6000 interactions in mouse) compared 
with the human data (50000-160,000 interactions in humans for the same set of 273 chemicals), 
whereas it was previously thought of as comparable numbers. 
Through the bioinformatics exercise, it brings to light the limitations and challenges 
present in cross-species modeling (e.g. data gaps in testing, transgenic studies, and even 
coverage of species-specific pathways). Hopefully, after the enrichments have been re-run, we 
may see some clusters form out of the human data subset that may be similarly detected from the 
mouse or rat data subsets. Thereafter, we can analyze for a primary set of gene targets useful for 
characterization, and determine whether or not a certain gene-form (e.g. DNA, RNA, or protein) 
of the gene targets contributes most to the characterization. To the larger picture, these outputs 
may help in understanding the mammary gland carcinogens and their similarities and differences 
in physiologic responses between human, mouse, or rat models. 
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APPENDIX 
Appendix 1: Orthologous Gene Targets 
- Intended target gene symbols that are non-human genes are highlighted in blue. 
- The rank column is used to order the groups of assay component endpoints in terms of their number of orthologous assays 
 
Assay component  
endpoint 
Intended target  
type 
Intended target  
subtype 
Intended target  
family 
Intended target  
subfamily 
Intended target  
gene ID 
Intended target  
gene symbol 
Rank 
ACEA_T47D_80hr_Positive pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
ATG_ERa_TRANS protein transcription factor nuclear receptor steroidal 2099 ESR1 1 
ATG_ERE_CIS protein transcription factor nuclear receptor steroidal 2099 ESR1 1 
NVS_NR_bER protein receptor nuclear receptor steroidal 407238 ESR1 1 
NVS_NR_hER protein receptor nuclear receptor steroidal 2099 ESR1 1 
NVS_NR_mERa protein receptor nuclear receptor steroidal 13982 Esr1 1 
OT_ER_ERaERa_0480 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ER_ERaERa_1440 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ER_ERaERb_0480 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ER_ERaERb_1440 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ERa_EREGFP_0120 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ERa_EREGFP_0480 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ERa_ERELUC_AG_1440 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
OT_ERa_ERELUC_ANT_1440 pathway pathway-specified nuclear receptor steroidal 2099 ESR1 1 
Tox21_ERa_BLA_Agonist_ch2 protein receptor nuclear receptor steroidal 2099 ESR1 1 
Tox21_ERa_BLA_Agonist_ratio protein receptor nuclear receptor steroidal 2099 ESR1 1 
Tox21_ERa_BLA_Antagonist_ratio protein receptor nuclear receptor steroidal 2099 ESR1 1 
Tox21_ERa_LUC_BG1_Agonist protein receptor nuclear receptor steroidal 2099 ESR1 1 
Tox21_ERa_LUC_BG1_Antagonist protein receptor nuclear receptor steroidal 2099 ESR1 1 
ATG_AR_TRANS protein transcription factor nuclear receptor steroidal 367 AR 2 
NVS_NR_cAR protein receptor nuclear receptor steroidal 747460 AR 2 
NVS_NR_hAR protein receptor nuclear receptor steroidal 367 AR 2 
NVS_NR_rAR protein receptor nuclear receptor steroidal 24208 Ar 2 
OT_AR_ARELUC_AG_1440 pathway pathway-specified nuclear receptor steroidal 367 AR 2 
OT_AR_ARSRC1_0480 pathway pathway-specified nuclear receptor steroidal 367 AR 2 
OT_AR_ARSRC1_0960 pathway pathway-specified nuclear receptor steroidal 367 AR 2 
Tox21_AR_BLA_Agonist_ch2 protein receptor nuclear receptor steroidal 367 AR 2 
Tox21_AR_BLA_Agonist_ratio protein receptor nuclear receptor steroidal 367 AR 2 
Tox21_AR_BLA_Antagonist_ratio protein receptor nuclear receptor steroidal 367 AR 2 
Tox21_AR_LUC_MDAKB2_Agonist protein receptor nuclear receptor steroidal 367 AR 2 
Tox21_AR_LUC_MDAKB2_Antagonist protein receptor nuclear receptor steroidal 367 AR 2 
54 
 
ATG_PPARg_TRANS protein transcription factor nuclear receptor non-steroidal 5468 PPARG 3 
ATG_PPRE_CIS protein transcription factor nuclear receptor non-steroidal 5468 PPARG 3 
NVS_NR_hPPARg protein receptor nuclear receptor non-steroidal 5468 PPARG 3 
OT_PPARg_PPARgSRC1_0480 pathway pathway-specified nuclear receptor non-steroidal 5468 PPARG 3 
OT_PPARg_PPARgSRC1_1440 pathway pathway-specified nuclear receptor non-steroidal 5468 PPARG 3 
Tox21_PPARg_BLA_Agonist_ch2 protein receptor nuclear receptor non-steroidal 5468 PPARG 3 
Tox21_PPARg_BLA_Agonist_ratio protein receptor nuclear receptor non-steroidal 5468 PPARG 3 
APR_p53Act_1h_dn pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
APR_p53Act_1h_up pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
APR_p53Act_24h_dn pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
APR_p53Act_24h_up pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
APR_p53Act_72h_dn pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
APR_p53Act_72h_up pathway pathway-specified dna binding tumor suppressor 7157 TP53 4 
ATG_p53_CIS protein transcription factor dna binding tumor suppressor 7157 TP53 4 
ATG_Ahr_CIS protein transcription factor dna binding basic helix-loop-helix protein 196 AHR 5 
Tox21_AhR protein receptor dna binding basic helix-loop-helix protein 196 AHR 5 
ATG_CAR_TRANS protein transcription factor nuclear receptor non-steroidal 9970 NR1I3 6 
ATG_PBREM_CIS protein transcription factor nuclear receptor non-steroidal 9970 NR1I3 6 
NVS_NR_hCAR_Agonist protein receptor nuclear receptor non-steroidal 9970 NR1I3 6 
NVS_NR_hCAR_Antagonist protein receptor nuclear receptor non-steroidal 9970 NR1I3 6 
ATG_DR5_CIS protein transcription factor nuclear receptor non-steroidal 5914 RARA 7 
ATG_RARa_TRANS protein transcription factor nuclear receptor non-steroidal 5914 RARA 7 
NVS_NR_hRAR_Antagonist protein receptor nuclear receptor non-steroidal 5914 RARA 7 
NVS_NR_hRARa_Agonist protein receptor nuclear receptor non-steroidal 5914 RARA 7 
ATG_FXR_TRANS protein transcription factor nuclear receptor non-steroidal 9971 NR1H4 8 
ATG_IR1_CIS protein transcription factor nuclear receptor non-steroidal 9971 NR1H4 8 
NVS_NR_hFXR_Agonist protein receptor nuclear receptor non-steroidal 9971 NR1H4 8 
NVS_NR_hFXR_Antagonist protein receptor nuclear receptor non-steroidal 9971 NR1H4 8 
ATG_GR_TRANS protein transcription factor nuclear receptor non-steroidal 2908 NR3C1 9 
ATG_GRE_CIS protein transcription factor nuclear receptor non-steroidal 2908 NR3C1 9 
NVS_NR_hGR protein receptor nuclear receptor non-steroidal 2908 NR3C1 9 
Tox21_GR_BLA_Agonist_ch2 protein receptor nuclear receptor non-steroidal 2908 NR3C1 9 
Tox21_GR_BLA_Agonist_ratio protein receptor nuclear receptor non-steroidal 2908 NR3C1 9 
Tox21_GR_BLA_Antagonist_ratio protein receptor nuclear receptor non-steroidal 2908 NR3C1 9 
ATG_PPARa_TRANS protein transcription factor nuclear receptor non-steroidal 5465 PPARA 10 
ATG_PPRE_CIS protein transcription factor nuclear receptor non-steroidal 5465 PPARA 10 
NVS_NR_hPPARa protein receptor nuclear receptor non-steroidal 5465 PPARA 10 
ATG_PXR_TRANS protein transcription factor nuclear receptor non-steroidal 8856 NR1I2 11 
ATG_PXRE_CIS protein transcription factor nuclear receptor non-steroidal 8856 NR1I2 11 
NVS_NR_hPXR protein receptor nuclear receptor non-steroidal 8856 NR1I2 11 
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ATG_RXRa_TRANS protein transcription factor nuclear receptor non-steroidal 6256 RXRA 12 
OT_NURR1_NURR1RXRa_0480 pathway pathway-specified nuclear receptor non-steroidal 6256 RXRA 12 
OT_NURR1_NURR1RXRa_1440 pathway pathway-specified nuclear receptor non-steroidal 6256 RXRA 12 
ATG_TGFb_CIS protein transcription factor growth factor transforming growth factor beta 7040 TGFB1 13 
BSK_BE3C_TGFb1_down protein protein-specified growth factor transforming growth factor beta 7040 TGFB1 13 
BSK_BE3C_TGFb1_up protein protein-specified growth factor transforming growth factor beta 7040 TGFB1 13 
BSK_KF3CT_TGFb1_down protein protein-specified growth factor transforming growth factor beta 7040 TGFB1 13 
BSK_KF3CT_TGFb1_up protein protein-specified growth factor transforming growth factor beta 7040 TGFB1 13 
ATG_THRa1_TRANS protein transcription factor nuclear receptor non-steroidal 7067 THRA 14 
NVS_NR_hTRa protein receptor nuclear receptor non-steroidal 7067 THRA 14 
Tox21_TR_LUC_GH3_Agonist protein receptor nuclear receptor non-steroidal 7067 THRA 14 
Tox21_TR_LUC_GH3_Antagonist protein receptor nuclear receptor non-steroidal 7067 THRA 14 
BSK_BE3C_MMP1_down protein protein-specified protease matrix metalloproteinase 4312 MMP1 15 
BSK_BE3C_MMP1_up protein protein-specified protease matrix metalloproteinase 4312 MMP1 15 
BSK_hDFCGF_MMP1_down protein protein-specified protease matrix metalloproteinase 4312 MMP1 15 
BSK_hDFCGF_MMP1_up protein protein-specified protease matrix metalloproteinase 4312 MMP1 15 
NVS_ENZ_hMMP1 protein enzyme protease matrix metalloproteinase 4312 MMP1 15 
NVS_ENZ_hMMP1_Activator protein enzyme protease matrix metalloproteinase 4312 MMP1 15 
BSK_KF3CT_MMP9_down protein protein-specified protease matrix metalloproteinase 4318 MMP9 16 
BSK_KF3CT_MMP9_up protein protein-specified protease matrix metalloproteinase 4318 MMP9 16 
NVS_ENZ_hMMP9 protein enzyme protease matrix metalloproteinase 4318 MMP9 16 
NVS_ENZ_hMMP9_Activator protein enzyme protease matrix metalloproteinase 4318 MMP9 16 
NVS_ADME_hCYP1A1 protein enzyme cyp xenobiotic metabolism 1543 CYP1A1 17 
NVS_ADME_hCYP1A1_Activator protein enzyme cyp xenobiotic metabolism 1543 CYP1A1 17 
NVS_ADME_rCYP1A1 protein enzyme cyp xenobiotic metabolism 24296 Cyp1a1 17 
NVS_ADME_rCYP1A1_Activator protein enzyme cyp xenobiotic metabolism 24296 Cyp1a1 17 
NVS_ADME_hCYP1A2 protein enzyme cyp xenobiotic metabolism 1544 CYP1A2 18 
NVS_ADME_hCYP1A2_Activator protein enzyme cyp xenobiotic metabolism 1544 CYP1A2 18 
NVS_ADME_rCYP1A2 protein enzyme cyp xenobiotic metabolism 24297 Cyp1a2 18 
NVS_ADME_rCYP1A2_Activator protein enzyme cyp xenobiotic metabolism 24297 Cyp1a2 18 
NVS_ADME_hCYP2E1 protein enzyme cyp xenobiotic metabolism 1571 CYP2E1 19 
NVS_ADME_hCYP2E1_Activator protein enzyme cyp xenobiotic metabolism 1571 CYP2E1 19 
NVS_ADME_rCYP2E1 protein enzyme cyp xenobiotic metabolism 25086 Cyp2e1 19 
NVS_ADME_rCYP2E1_Activator protein enzyme cyp xenobiotic metabolism 25086 Cyp2e1 19 
NVS_ENZ_hAChE protein enzyme esterase acetylcholinesterase 43 ACHE 20 
NVS_ENZ_hAChE_Activator protein enzyme esterase acetylcholinesterase 43 ACHE 20 
NVS_ENZ_rAChE protein enzyme esterase acetylcholinesterase 83817 Ache 20 
NVS_ENZ_rAChE_Activator protein enzyme esterase acetylcholinesterase 83817 Ache 20 
NVS_GPCR_bAdoR_NonSelective protein receptor gpcr rhodopsin-like receptor 282133 ADORA1 21 
NVS_GPCR_hAdoRA1 protein receptor gpcr rhodopsin-like receptor 134 ADORA1 21 
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NVS_GPCR_bDR_NonSelective protein receptor gpcr rhodopsin-like receptor 281125 DRD1 22 
NVS_GPCR_hDRD1 protein receptor gpcr rhodopsin-like receptor 1812 DRD1 22 
NVS_GPCR_bH1 protein receptor gpcr rhodopsin-like receptor 281231 HRH1 23 
NVS_GPCR_hH1 protein receptor gpcr rhodopsin-like receptor 3269 HRH1 23 
NVS_GPCR_gLTB4 protein receptor gpcr rhodopsin-like receptor 100379538 Ltb4r 24 
NVS_GPCR_hLTB4_BLT1 protein receptor gpcr rhodopsin-like receptor 1241 LTB4R 24 
NVS_GPCR_gMPeripheral_NonSelective protein receptor gpcr rhodopsin-like receptor 100379235 Chrm3 25 
NVS_GPCR_hM3 protein receptor gpcr rhodopsin-like receptor 1131 CHRM3 25 
NVS_GPCR_hAdra2A protein receptor gpcr rhodopsin-like receptor 150 ADRA2A 26 
NVS_GPCR_rAdra2_NonSelective protein receptor gpcr rhodopsin-like receptor 25083 Adra2a 26 
NVS_GPCR_hAdrb1 protein receptor gpcr rhodopsin-like receptor 153 ADRB1 27 
NVS_GPCR_rAdrb_NonSelective protein receptor gpcr rhodopsin-like receptor 24925 Adrb1 27 
NVS_GPCR_hNTS protein receptor gpcr rhodopsin-like receptor 4923 NTSR1 28 
NVS_GPCR_rNTS protein receptor gpcr rhodopsin-like receptor 366274 Ntsr1 28 
NVS_GPCR_hOpiate_mu protein receptor gpcr rhodopsin-like receptor 4988 OPRM1 29 
NVS_GPCR_rOpiate_NonSelective protein receptor gpcr rhodopsin-like receptor 25601 Oprm1 29 
NVS_GPCR_rOpiate_NonSelectiveNa protein receptor gpcr rhodopsin-like receptor 25601 Oprm1 29 
NVS_GPCR_hV1A protein receptor gpcr rhodopsin-like receptor 552 AVPR1A 30 
NVS_GPCR_rV1 protein receptor gpcr rhodopsin-like receptor 25107 Avpr1a 30 
NVS_LGIC_bGABAR_Agonist protein receptor ion channel ligand-gated ion channel 282235 GABRA1 31 
NVS_LGIC_bGABARa1 protein receptor ion channel ligand-gated ion channel 282235 GABRA1 31 
NVS_LGIC_rGABAR_NonSelective protein receptor ion channel ligand-gated ion channel 29705 Gabra1 31 
NVS_MP_hPBR protein transporter transporter cholesterol transporter 706 TSPO 32 
NVS_MP_rPBR protein transporter transporter cholesterol transporter 24230 Tspo 32 
NVS_NR_bPR protein receptor nuclear receptor non-steroidal 280895 PGR 33 
NVS_NR_hPR protein receptor nuclear receptor non-steroidal 5241 PGR 33 
NVS_TR_gDAT protein transporter transporter neurotransmitter transporter 100714898 Slc6a3 34 
NVS_TR_hDAT protein transporter transporter neurotransmitter transporter 6531 SLC6A3 34 
NVS_TR_hAdoT protein transporter transporter nucleoside transporter 2030 SLC29A1 35 
NVS_TR_rAdoT protein transporter transporter nucleoside transporter 63997 Slc29a1 35 
NVS_TR_hNET protein transporter transporter neurotransmitter transporter 6530 SLC6A2 36 
NVS_TR_rNET protein transporter transporter neurotransmitter transporter 83511 Slc6a2 36 
NVS_TR_hSERT protein transporter transporter neurotransmitter transporter 6532 SLC6A4 37 
NVS_TR_rSERT protein transporter transporter neurotransmitter transporter 25553 Slc6a4 37 
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 Appendix 2: R Script for a Global Principle Components Analysis of ToxCast Assay Data 
#### Prior to running this code, the “Ontology_realm” E-drive was established on an external  
#### hard drive. It contains the ToxCast Phase II Data release screening data, design info data  
#### file, and target info data files were pre-processed to calculate –Log10(value/100000)  
#### transformed values. 
 
# Progression of objects: 
# 
# Design_info -> Design_melt -> Design_melted merges with Target_melted -> AxM 
# Target_info -> Target_melt -> Target_melted merges with Design_melted -> AxM 
# AxM merges into MxC_prep -> MxC_prep -> MxC (end) 
# DATA_LEVEL6 -> DL6 
# DL6 + AxM -> MxC_prep 
 
# install.packages("Rtools") 
# install.packages("devtools") 
# install.packages("reshape2") 
# install.packages("Rcpp") 
library(Rcpp) 
library(devtools) 
 
# set directory # 
annotation.dir <- "E:/Ontology realm" 
setwd(annotation.dir) 
 
 
# Read in Data release and Annotations# 
list.files() 
DATA_LEVEL6 <- read.csv ("ToxCast_E1k_1858_LEVEL6_AC50_COMPLETE_2014MAR17.csv", 
header=TRUE) 
head(DATA_LEVEL6)[1:10] 
dim(DATA_LEVEL6) 
 
Design_info <- read.csv ("toxcast_assay_annotation_study_design_Mar2014.csv", header=TRUE)  
Design_info <- Design_info[order(Design_info$assay_component_endpoint_name),] 
Target_info <- read.csv ("toxcast_assay_annotation_target_info_Mar2014.csv", header=TRUE) 
Target_info <- Target_info[order(Target_info$assay_component_endpoint_name),] 
 
 
# Merging the BSK CASM3C gaps with the SM3C data # 
BSK_mod <- colnames(DATA_LEVEL6)[grep("BSK_CASM3C|BSK_SM3C",colnames(DATA_LEVEL6))] 
#BSK_mod 
sum(!is.na(DATA_LEVEL6[,BSK_mod[1]])) #775 chemicals with CASM3C data 
sum(!is.na(DATA_LEVEL6[,BSK_mod[29]])) #292 chemicals with SM3C data 
 
for (i in 1:28){ #for each line of CASM3C that is NA, replace with the matching SM3C data 
  j <- i+28 
  DATA_LEVEL6[is.na(DATA_LEVEL6[,BSK_mod[1]]),BSK_mod[i]] <- 
DATA_LEVEL6[is.na(DATA_LEVEL6[,BSK_mod[1]]),BSK_mod[j]] 
} 
sum(!is.na(DATA_LEVEL6[,BSK_mod[1]])) #1058 chemicals with CASM3C data 
58 
 
 
# id and remove APR 1hr (Phase 1 only) data # 
APR_mod <- colnames(DATA_LEVEL6)[grep("APR_",colnames(DATA_LEVEL6))] 
APR_mod <- APR_mod[grep("_1h_",APR_mod)] 
sum(!is.na(DATA_LEVEL6[,APR_mod[15]])) #292 chemicals with each APR 1hr assay 
 
# remove the SM3C and APR_1hr data from further usage # 
DATA_LEVEL6 <- DATA_LEVEL6[,!colnames(DATA_LEVEL6) %in% BSK_mod[29:56]] 
DATA_LEVEL6 <- DATA_LEVEL6[,!colnames(DATA_LEVEL6) %in% APR_mod] 
rm(BSK_mod, APR_mod, i, j) 
 
 
# create annotation:term pairs # 
desc_term_pair <- function (x) { 
  y <- matrix(NA,nrow=nrow(x),ncol=ncol(x)) 
  for (i in 1: nrow(x)) { 
    for (j in 1:length(x)) { 
      #y[i,j] <- toupper(paste(names(x)[j],":",x[i,j],sep="")) 
      y[i,j] <- paste(names(x)[j],":",x[i,j],sep="") 
    } 
  } 
  colnames(y) <- colnames(x) 
  y <- cbind(as.character(x$assay_component_endpoint_name),y) 
  colnames(y)[1] <- "assay_component_endpoint" 
  y <- y[, colnames(y)!="assay_component_endpoint_name"] 
} 
Design_melt <- desc_term_pair(Design_info) 
head(Design_melt) 
 
Target_melt <- desc_term_pair(Target_info) 
head(Target_melt) 
 
 
# Separate out the description variables, annotation IDs, and other variables to be removed from PCA# 
remove <- c("_desc","assay_source_long_name","assay_name","assay_component_name" 
            ,"organism_id","target_gene_id" 
            ,"wavelength_","key_assay_","key_positive_control","dilution_solvent_","timepoint_" 
            ) 
 
Design_melt <- as.matrix(Design_melt[,grep(gsub(", ","\\|",toString(remove)),colnames(Design_melt), 
invert=TRUE)]) 
Target_melt <- as.matrix(Target_melt[,grep(gsub(", ","\\|",toString(remove)),colnames(Target_melt), 
invert=TRUE)]) 
 
colnames(Design_melt) 
colnames(Target_melt) 
 
 
# remove duplicate columns except for "the "assay_component_endpoint" # 
colnames(Design_melt)[colnames(Design_melt) %in% colnames(Target_melt)] 
remove <- colnames(Design_melt)[colnames(Design_melt) %in% colnames(Target_melt)][-1] 
Target_melt <- Target_melt[,!colnames(Target_melt) %in% remove] 
Design_melt <- as.data.frame(Design_melt) 
Target_melt <- as.data.frame(Target_melt) 
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# reshape the matrices # 
library(reshape2) 
Melted <- function(x) { 
  y <- melt(x, id="assay_component_endpoint", na.rm=FALSE) 
  y <- dcast(y, assay_component_endpoint~value, function(x) 1, fill=0) 
} 
 
Design_melted <- Melted(Design_melt) 
head(Design_melted,30) 
 
Target_melted <- Melted(Target_melt) 
head(Target_melted,30) 
 
 
# merge the two matrices for uniform representation of Design and Target # 
AxM <- merge(Design_melted, Target_melted, by="assay_component_endpoint", all=TRUE) 
rownames(AxM) <- AxM$assay_component_endpoint 
colnames(AxM) 
dim(AxM) 
head(AxM,10)[1:10] 
 
plot(colSums(AxM[,-1]), xlim=c(0,300), #ylim=c(0,100),  
     ylab="No. of Assays", xlab="AxM term id", main="No. of Assays across the AxM terms") 
summary(colSums(AxM[,-1])) 
 
 
# checking the format of the AxC table # 
tail(DATA_LEVEL6) 
retired <- colnames(DATA_LEVEL6)[!colnames(DATA_LEVEL6) %in% rownames(AxM)][-(1:3)] 
retired 
#### Note: ATG perc series, Tox21 ch1+ch2, & Tox21 mito fitc+rhodamine  
#### have data released, but not the annotations for them 
 
 
# Generate the MxC matrix # 
names(AxM)  
AxM[1:5,1:5] #still has the assay_component_endpoint column 
AxM[,"assay_component_endpoint"] 
dim(AxM) 
dim(DATA_LEVEL6) 
 
 
# Generate the chemical data as.numeric and as AxC # 
head(DATA_LEVEL6)[1:6] 
DL6 <- matrix(0, ncol=nrow(DATA_LEVEL6), nrow=ncol(DATA_LEVEL6)-3) 
for (i in 1:nrow(DATA_LEVEL6)){ 
  x <- lapply(DATA_LEVEL6[i,4:ncol(DATA_LEVEL6)], as.character) 
  x <- unlist(lapply(x, as.numeric)) 
  DL6[,i] <- x 
} 
class(DL6[,1845]) #check to see if it is numeric 
tail(DL6) 
DL6 <- as.data.frame(DL6) 
rownames(DL6) <- colnames(DATA_LEVEL6)[-(1:3)] 
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# Excluding the retired assays and selecting the chemical identifiers to keep # 
colnames(DL6) <- DATA_LEVEL6[,"TS_ChemName"] #assigning the chemical column names 
DL6 <- cbind(rownames(DL6),DL6) 
head(DL6)[1:5] 
colnames(DL6)[1] <- "assay_component_endpoint" 
DL6 <- DL6[!rownames(DL6) %in% retired,] #removing retired assays 
DL6[1:10,1:10] 
dim(DL6) 
 
 
# Remove the chemicals with too many NAs # 
plot(colSums(is.na(DL6)), 
     xlab = "Chemical ID", ylab = "No of NA values for Assays", main = "Distribution of NA chemical average 
values")  
summary(colSums(is.na(DL6))) 
  #graph and summary table suggests that the magic cutoff numbers are 100, 150, 300, and 600) 
maybeE1K <- colnames(DL6)[colSums(is.na(DL6))>500] 
length(maybeE1K) 
DL6 <- as.data.frame(DL6[,!colnames(DL6) %in% maybeE1K]) 
length(colnames(DL6)) #1059 + assay_component_endpoint_names 
 
 
# Generating the wide file # 
colnames(DL6)[1:10] 
dim(AxM) 
AxM <- AxM[rownames(AxM) %in% rownames(DL6),] 
 
filtered <- colnames(AxM[,-1])[colSums(AxM[,-1])<1] 
length(filtered) 
filtered[1:100] 
AxM <- as.data.frame(AxM[,!colnames(AxM) %in% filtered]) 
AxM[,1] 
 
AxM[1:2] 
MxC_prep <- merge(DL6, AxM, by="assay_component_endpoint") 
head(MxC_prep)[c(1:10,1060:1069)] 
dim(DL6) # 783 by 1060 
 
 
# Getting rid of the 'assay_component_endpoint' columns # 
row.names(MxC_prep) <- MxC_prep[,"assay_component_endpoint"] 
MxC_prep <- MxC_prep[,!names(MxC_prep) %in% "assay_component_endpoint"] 
DL6 <- DL6[,!names(DL6) %in% "assay_component_endpoint"] 
AxM <- AxM[,!names(AxM) %in% "assay_component_endpoint"] 
head(MxC_prep)[1:5] 
 
MxC <- matrix(NA, nrow=ncol(AxM), ncol=ncol(DL6)) 
dim(MxC) # Metadata Annotations by Chemical data; AxM by dataset 
 
dim(DL6) # Assays(+retired) by Chemical data 
dim(AxM) # Assays by Metadata Annotations 
dim(MxC_prep) # assays incommon by [Chemical data + Metadata Annotation] 
MxC_prep[,1060] 
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colnames(MxC) <- colnames(DL6) 
rownames(MxC) <- colnames(AxM) 
 
# Calculate the average(-log10(AC50)) for each chemical to annotation term # 
x <- MxC_prep[,1:1059] 
ptm <- proc.time()   
  for (j in 1000:ncol(AxM)) { 
    k <- j+ncol(DL6) 
    y = MxC_prep[,k] 
    MxC_p <- data.frame(x,y) 
    MxC_p <- MxC_p[which(MxC_p$y=="1"),] 
    z <- aggregate(MxC_p, by=list(MxC_p[,"y"]), FUN=mean, na.rm=TRUE) 
    MxC[j,] <- unlist(z[1,2:1060]) 
  } 
proc.time()-ptm 
MxC[1000:1050,1:5] 
 
rownames(MxC)[is.na(rowSums(MxC))] 
 
rm(i,j,k,x,y,z,MxC_p,ptm) 
 
 
# writing the MxC table # 
write.csv(MxC,"MetaxChem_averagescores.csv")  
# PCA prep #1 
install.packages("gplots") 
 
# Check for the number of NAs per chemical # 
plot(colSums(is.na(MxC))) 
 
# There are still too many NA and NaN values. Trying Matt's solution: Avg()=>NaN) # 
MxC_1 <- MxC 
for (i in 1:nrow(MxC)) { 
  if (sum( is.na(MxC[i,]) )>0) { 
    MxC_avg <- mean(MxC[i,],na.rm=TRUE) 
    MxC_1[i,] <- as.numeric(gsub(NaN,MxC_avg, unlist(MxC_1[i,]))) 
  } 
} 
rm(i) 
MxC_1[1:10,1:10] 
MxC_1 <- t(MxC_1) 
  rownames(MxC_1)=NULL #remove the chemical names 
  remove <- colnames(MxC_1)[colSums(MxC_1)==0] #remove features that have 0 hits 
MxC_2 <- MxC_1[,!colnames(MxC_1) %in% remove] 
MxC_2 
write.csv(MxC_2, "MxC_data.csv") 
 
try1 <- matrix(NA,ncol=ncol(MxC_2),nrow=2) 
for (i in 1:ncol(MxC_2)){ 
  try1[1,i] <- mean(MxC_2[,i],) 
  try1[2,i] <- sd(MxC_2[,i]) 
} 
 
plot(try1[1,], col="blue") 
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par(new=T) 
plot(try1[2,], col="red") 
par(new=F) 
 
MxC_pca <- prcomp(MxC_2,center=TRUE, scale=TRUE) 
tail(MxC_pca) 
names(MxC_pca) 
 
PCA_loading <- MxC_pca$rotation #is.matrix 
length(PCA_loading[,1]) 
write.csv(PCA_loading, "MxC_loading.csv") 
 
Vimportance <- summary(MxC_pca) #generates the importance column 
Vimportance <- Vimportance$importance #is.matrix 
rownames(Vimportance) 
write.csv(Vimportance, "MxC_importance.csv") 
 
 
# examining the data # 
dimnames(PCA_loading) 
pairs(PCA_loading[,1:5]) #scatterplot of PC1 thru PC10 
 
library(gplots) 
my_palette <- colorRampPalette(c("dodger blue", "white", "orange"))(n = 299) 
PCA_heat <- heatmap.2(PCA_loading[,1:5],dendrogram=c("row"),Rowv=TRUE,Colv=FALSE,trace="none", 
col=my_palette, 
                      density.info="none", denscol=FALSE, key=TRUE)  
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